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Introduction
Patients with chronic renal failure (CRF) are at increased risk for developing 
cardiovascular disease. A decreased glomerular fi ltration rate is (GFR) is recog-
nized as an independent cardiovascular risk factor. The increased cardiovascu-
lar risk is already apparent in patients with moderate renal insuffi ciency (GFR 
<60 mL/min/1.73m2 ), and is most prominent in patients with end-stage renal 
disease (ESRD) (1-3). High concentration of serum cholesterol is one of the 
most widely recognized cardiovascular risk factors. There is overwhelming evi-
dence to support serum cholesterol lowering treatment in patients with 
increased cardiovascular risk (4-9). It therefore seems logical to extrapolate 
these fi ndings of the ‘bad’ effects of cholesterol, to patients with ESRD as well. 
However, there is some evidence to suggest that higher cholesterol per se may 
not be such an important risk factor in patients with ESRD compared to other 
subjects with an increased cardiovascular risk. In fact, in some studies in ESRD 
a low serum cholesterol was associated with increased mortality, suggesting 
‘good’ effects of higher cholesterol levels on survival rate (10;11). Furthermore, 
a recent randomized trial reported no benefi t from therapy lowering serum cho-
lesterol in diabetic hemodialysis patients (12). 
The dispute on cholesterol in patients with ESRD has become even more com-
plicated since low-density lipoprotein (LDL) particles in these patients may be 
altered, and become ‘ugly’, through increased oxidative stress, which is char-
acteristic for dialysis patients. This results in the formation of small, dense, 
oxidized LDL-particles that are considered to be highly atherogenic and there-
fore play an important role in the development of atherosclerosis (13;14). 
In this review, we summarize the data on serum cholesterol as a possible car-
diovascular risk factor and the effect of treatment with statins on cardiovascular 
outcome in patients with ESRD. We put these data in perspective and discuss 
increased oxidative stress in more detail as a potentially important modifi er.
Cardiovascular risk profi le in ESRD
Cardiovascular morbidity and mortality in ESRD
Despite the availability of sophisticated techniques for renal replacement ther-
apy (hemodialysis, peritoneal dialysis, and renal transplantation), life expect-
ancy of patients with ESRD on hemodialysis and peritoneal dialysis remains 
poor, with only a moderate amelioration after renal transplantation. The annual 
mortality rate in the dialysis population is about 20%. Approximately 50% of 
these deaths are caused by cardiovascular disease. This makes cardiovascular 
mortality 10-30 times more prevalent in patients with ESRD compared to the 
general population (15). 
The poor cardiovascular outcome in patients with ESRD is both attributed to an 
increased incidence and prevalence of cardiovascular disease as well as a high 
9
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case fatality rate. In patients treated with hemodialysis or peritoneal dialysis, 
the prevalence of overt coronary artery disease is approximately 40% (15). After 
a cardiovascular event, survival in ESRD is poor: in patients with ESRD mortal-
ity rates after a myocardial infarction have been reported to be 59% and 90% 
after 1 and 5 years respectively (16). The increased prevalence of cardiovascu-
lar disease is not restricted to patients with ESRD, but is already apparent in 
patients with mild to moderate renal insuffi ciency (17-21). Thus, the process of 
atherosclerotic cardiovascular disease starts long before patients reach ESRD. 
Moreover, it is important to realize that the arterial lesions in patients with ESRD 
differ from those observed in patients with classical coronary artery disease 
(22;23). In patients with classical atherosclerotic disease, the vascular plaques 
have the typical aspects of atheromatous or fi broatheromatous plaques, with a 
prominent presence of lipid accumulation. In contrast, patients with ESRD have 
typical calcifi ed plaques, predominantly composed of fi brous tissue and calci-
um deposits (23). Furthermore, thickening of intima and media of the vessel 
wall, with subsequent narrowing of the lumen, is more prominent in ESRD. In 
addition to atherosclerotic or calcifi ed vascular disease, patients with ESRD are 
more prone to the development of left ventricular hypertrophy (LVH) as a result 
of hypertension and anemia. Both tissue calcifi cation and LVH contribute to the 
development of myocardial fi brosis, diastolic dysfunction and left ventricular 
conduction abnormalities. This not only leads to heart failure, but more impor-
tantly may predispose to potentially lethal primary cardiac rhythm disturbances 
(22;24). Notably, although mortality in patients with ESRD is often attributed to 
cardiovascular disease, many patients die suddenly with presumed cardiac 
arrest, and only a minority die from typical atherosclerotic diseases such as 
myocardial infarction or stroke. This is refl ected by data of the recent USRDS 
registry, showing that in 2005, 7.2% of dialysis patients died from cardiac arrest 
or cardiac arrhythmia, whereas myocardial infarction or coronary heart disease 
were the cause of death in 2.9% of the patients (25).
Cardiovascular risk factors in ESRD
In discussing cardiovascular risk factors in patients with ESRD a distinction can 
be made between traditional and non-traditional risk factors. The traditional risk 
factors are defi ned by epidemiological studies such as the Framingham study 
and infl uence the development of cardiovascular disease in the general popula-
tion. These risk factors may also be applicable to the dialysis population. The 
CHOICE study showed that the majority of dialysis patients had one or more of 
the traditional cardiovascular risk factors: 54% of the patients had diabetes 
mellitus, 33% had a low serum HDL-cholesterol, 96% suffered from hyperten-
sion, 22% had left ventricular hypertrophy and the average age of the patients 
at the start of dialysis therapy was 60 years. Of note, an increased LDL-choles-
terol (>4.2 mmol/l) was observed in only 11 % of patients (26). Because of the 
large difference in cardiovascular risk between the general population and 
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patients with CRF and ESRD, it was postulated that in the latter patients addi-
tional so called non-traditional cardiovascular risk factors must be present. 
Examples of these non-traditional risk factors include calcium, phosphorus, 
hyperparathyroidism, vitamin D, and C-reactive protein (CRP). It has been sug-
gested that these non-traditional risk factors could (partly) explain the large 
difference in cardiovascular disease between the general and the renal popula-
tion. Little attention is given to alterations in lipid composition in ESRD. 
Characteristics of the lipid profi le in ESRD
In patients with ESRD, dyslipidemia is a common fi nding. This is caused by 
alterations in the metabolism and the composition of the plasma lipoproteins. 
The typical, traditional lipid profi le in patients with ESRD is characterized by 
normal or low concentrations of LDL-cholesterol, increased concentrations of 
triglycerides (TG) due to elevated levels of very-low-density lipoprotein (VLDL) 
and intermediate-density lipoprotein (IDL) and decreased high-density lipopro-
tein cholesterol (HDL). The LDL composition is abnormal and characterized by 
the presence of small-dense LDL particles (fi gure 1). 
Figure 1.  Lipid abnormalities in patients with ESRD (27-30). Levels are given as percentage com-
pared to normal
There are slight differences between patients treated with hemodialysis and 
those treated with peritoneal dialysis: levels of LDL-cholesterol and small-
dense LDL are higher and levels of HDL-cholesterol are lower in patients 
on peritoneal dialysis compared to patients on hemodialysis (27-30). Most 
studies which describe the abnormalities in lipoproteins in ESRD, focus on the 
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absolute levels of lipoproteins but do not mention possible alterations in the 
state of these lipoproteins (e.g. oxidized or carbamylated), which may affect 
early onset of atherosclerosis. 
Impact of dyslipidemia on cardiovascular disease in ESRD
Several studies reported an association between dyslipidemia and surrogate 
cardiovascular endpoints. Tamashiro et al. described that in chronic hemodialy-
sis patients the progression of coronary arteries calcifi cation was related to high 
concentrations of TG and low concentrations of HDL (31). These data were 
confi rmed in peritoneal dialysis patients (32). Although these studies suggested 
that dyslipidemia may affect cardiovascular outcome in patients with ESRD, 
many studies have failed to fi nd a positive association between the traditional 
lipid profi le (total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycer-
ides) and cardiovascular endpoints in patients with ESRD (33-36). In fact, these 
studies often noted a seemingly inverse relationship, low cholesterol levels 
being associated with higher mortality rates (10). Although these observations 
have been used as arguments against a contributory role of cholesterol in car-
diovascular disease in patients with ESRD, it is now clear that this so called 
reverse epidemiology is explained by the confounding effects of malnutrition 
and infl ammation. 
Many patients with ESRD have evidence of malnourishment and chronic infl am-
mation. Clinically these patients are characterized by lower body weight, lower 
blood pressure, low cholesterol, low serum albumin and elevated CRP. Survival 
rates are low in these patients. With this in mind, it is no surprise that in patients 
with ESRD the presence of this chronic infl ammatory state confounds normal 
associations and causes reverse epidemiology. Recent studies demonstrate this 
clearly. Liu et al. observed a higher cardiovascular event rate in ESRD patients 
with low serum cholesterol. However, when restricting the analysis to patients 
without infl ammation and malnutrition they observed the ‘normal’ positive asso-
ciation between serum cholesterol and cardiovascular mortality (37). Iseki et al. 
confi rmed this by showing that high concentrations of cholesterol were associ-
ated with a higher mortality risk in patients with normal serum albumin levels 
(10). These studies suggest that in the well-nourished, non-infl ammatory dialysis 
patients, hypercholesterolemia is a cardiovascular risk factor. 
Reverse epidemiology is only one part of the story. The lack of an association 
between cholesterol and cardiovascular risk may also be explained by the con-
tributions of other lipoproteins. As mentioned above, in patients with ESRD 
levels of IDL, small-dense LDL and Lp(a) are increased. Several studies have 
reported a positive association between some of these lipoproteins and cardio-
vascular disease. 
In patients with elevated levels of IDL there is evidence of atherosclerotic dis-
ease. Moreover, Shoji et al. showed that IDL is an independent risk factor for 
12 Chapter 1
24PJ67 IS1 Netrologie.indd   12 21-01-2008   08:38:14
aortic sclerosis in hemodialysis patients (38). In patients with ESRD, Lp(a) is 
a risk factor for cardiovascular disease and mortality (39-42). Finally, the highly 
atherogenic LDL subclass, small-dense LDL, is present in hemodialysis patients 
(29). In ESRD, these ‘alternative’ lipoproteins may fulfi l a more important role in 
the development of cardiovascular disease than LDL. Therefore, it may be 
important to focus also on these non-traditional lipid parameters. 
Moreover, biochemical modifi cations of LDL, not refl ected by total and LDL-
cholesterol levels, may offer another explanation for the increased cardiovascu-
lar risk in patients with ESRD. The most important process involves the oxida-
tion of lipids (discussed below in more detail).
Effect of treatment of dyslipidemia in CRF and ESRD with statins
In the general population, treatment with HMG CoA reductase inhibitors or 
statins, is one of the cornerstones in the strategies to reduce cardiovascular 
risk, both in primary and secondary prevention (4-9). Since patients with CRF 
are at a high risk to develop cardiovascular disease, treatment of all risk factors 
including serum cholesterol seems warranted. Indeed, most guidelines recom-
mend aggressive treatment of LDL-cholesterol. However, treatment with HMG 
CoA reductase inhibitors in patients with CRF is still open for debate, since for 
this subgroup the data on effect of treatment are scarce, as most trials exclud-
ed patients with severe renal insuffi ciency. Posthoc subgroup analysis of the 
Heart Protection Study (HPS) and the Cholesterol And Recurrent Events trial 
(CARE) indicated that cholesterol lowering was benefi cial in patients with mod-
erate renal insuffi ciency (GFR 30-60 ml/min) (6;43;44). However, few data are 
available to allow conclusions for patients with GFR < 30 ml/min. 
What is known about the treatment of serum cholesterol in patients 
with ESRD? 
A Cochrane review, published in 2004, concluded that statins decreased serum 
cholesterol in dialysis patients as effectively as in the general population. With 
respect to the effects of statins on (cardiovascular) mortality no conclusions 
could be drawn because of the lack of studies with hard clinical endpoints 
(45).
The effects of lipid-lowering therapy with statins on surrogate endpoints sug-
gested potential benefi ts. Achenbach et al. demonstrated that treatment with 
cerivastatin reduced the progression of coronary calcium deposition (46). Few 
studies have evaluated the effects of statin therapy on cardiovascular end-
points in patients with ESRD. Two uncontrolled studies reported a reduced 
cardiovascular mortality in patients who had been treated with statins (47;48). 
This benefi t was limited to patients with a previous history of cardiovascular 
disease. Although appealing, these data do not allow fi rm conclusions. Although 
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the authors used multivariate analysis to adjust for known risk factors, con-
founding could not be excluded. In fact, only 10% of the ESRD patients used 
a statin, and those patients had higher cholesterol levels and less signs of mal-
nourishment. Thus, the abovementioned reverse epidemiology might explain 
the relationship between survival and statin use in these studies. 
The ongoing Study of Heart and Renal Protection (SHARP) is designed to study 
the effects of treatment with simvastatin and ezetimibe on cardiovascular dis-
ease in patients with chronic renal failure. Biochemical safety and effi cacy have 
been shown (49;50). The more interesting and important results of this study 
can be expected after 2007. The AURORA study is an ongoing randomized 
controlled trial, which will evaluate the effi cacy of rosuvastatin in preventing 
cardiovascular events in hemodialysis patients (51). Results of this study can 
be expected in the next years.
So far, only one randomized controlled trial has evaluated the effect of treat-
ment with a statin on clinical endpoints in hemodialysis patients (12). Results of 
Die Deutsche Diabetes Dialysis study (4D study) were reported in 2005. 
The 4D study included 1255 patients with type 2 diabetes mellitus on main-
tenance hemodialysis therapy. Patients with serum LDL-cholesterol levels 
between 2.1 mmol/l and 4.9 mmol/l were randomized for treatment with ator-
vastatin 20 mg or placebo. Primary endpoint was a composite of death from 
cardiac causes, non-fatal myocardial infarction and stroke. Secondary end-
points included death from all causes and all cardiac and cerebrovascular 
events combined. Atorvastatin effectively lowered serum cholesterol, was safe 
and well tolerated. Obviously, a reduction in cardiovascular endpoints was 
expected in view of the high cardiovascular risk profi le of these patients. Disap-
pointingly, treatment with atorvastatin did not signifi cantly reduce the incidence 
of primary endpoints. The results of this study are often quoted and used as 
argument against cholesterol lowering in patients with ESRD. However, it is 
important to take a closer look at the data. Table 1 provides data on specifi c 
causes of death reported in the 4D study. Mortality was very high in the study 
population. It is evident that sudden death was more frequent than death from 
coronary heart disease. Atorvastatin lowered the incidence of death due to 
coronary heart disease, but had no effect on sudden death. As for the preven-
tion of coronary death, treatment with atorvastatin was associated with an 
absolute risk reduction (ARR) of 2.2%, with a calculated number needed to 
treat (NNT) of 45. Admittedly, there was no overall statistically signifi cant sur-
vival advantage in the atorvastatin treated group, which is readily explained by 
the high incidence of death from non-atherosclerotic disease. Still, the analysis 
may suggest that also in patients with ESRD statins are able to modify the proc-
ess of classical atheromatous disease and lower the incidence of classical, 
atherosclerotic coronary heart disease. In contrast, cholesterol lowering is 
unlikely to infl uence myocardial fi brosis and prevent death from cardiac arrhyth-
mias. 
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Table 1.  Coronary mortality and sudden death in the Deutsche Diabetes Dialysis study (12)
Placebo 
(n=636)
Atorvastatin 
(n=619)
ARRa NNTb
Cardiac death due 
to atherosclerotic 
disease
Death due to coronary heart 
disease
5 (0.8%) 1 (0.2%)
Death due to intervention for 
coronary heart disease
4 (0.6%) 3 (0.5%)
Fatal myocardial infarction 33 (5.2%) 23 (3.7%)
Subtotal 42 (6.6%) 27 (4.4%) 2.2% 45
Non-atherosclerotic 
death
Sudden death 83 (13.1%) 77 (12.4) 0.6% 164
Subgroup 1+2 Total 125 (19.7%) 104 (16.8%) 2.9% 35
a absolute risk reduction
b numbers needed to treat
Another interesting way of putting the results of the 4D study in perspective is 
a comparison between the 4D study and the Cholesterol Treatment Trialists’ 
study (CTT), a meta-analysis of 14 randomized controlled trials (RCT’s) of stat-
ins (table 2) (52). Specifi cally, when focussing on overall mortality and mortality 
due to coronary heart disease, it can be expected that cholesterol lowering is 
primarily benefi cial by reducing the risk of an ischemic atherosclerotic cardio-
vascular event. When calculating ARR of coronary deaths, the results of the 4D 
study appear comparable to the other studies with a ARR of 2.3% as compared 
to 0.4 – 3.5% in other studies. However, coronary death rate was only a small 
fraction of total mortality in the 4D study (11%). The overall mortality in the 4D 
study as well as the percentage of sudden deaths is impressive, whereas the 
absolute coronary event rate is rather low. One may thus conclude that, with 
respect to coronary events, the 4D study was clearly underpowered. 
Table 2.  A comparison of the mortality due to coronary heart disease and any death between the 
Deutsche Diabetes Dialysis study (12) and the Cholesterol Treatment Trialists’study (52)
CTT Placebo 
(n=45002)
Statin 
(n=45054)
ARRa NNTb
Death due to coronary heart disease 1960 (4.4%) 1548 (3.4%) 0.9% 109
Any death 4354 (9.7%) 3832 (8.5%) 1.1% 89
4D Placebo 
(n=636)
Atorvastatin 
(n=619)
Death due to coronary heart disease 42 (6.6%) 27 (4.4%) 2.2% 45
Any death 320 (50.3%) 297 (48.0%) 2.3% 43
a absolute risk reduction
b numbers needed to treat 
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Furthermore, benefi ts of cholesterol lowering may not be expected in patients 
with the highest risk i.e. patients with chronic infl ammation and malnutrition on 
dialysis. As mentioned earlier, based on the data of Liu and Iseki, cholesterol 
lowering might be of benefi t in patients with absent infl ammation and no signs 
of chronic infl ammation, most likely patients with a higher life expectancy 
(10;37). In this respect the survival curve depicted in the CTT is interesting for 
the reported time-frame of protection. Although benefi ts of cholesterol lowering 
were evident within the fi rst year, the effects were greater in subsequent years. 
Short-term mortality rate is high in patients with ESRD and in particular in 
patients with diabetic disease or patients with malnutrition and infl ammation. 
Any benefi t of statin treatment in patients with ESRD will thus only become 
apparent after many years, in patients who are well nourished, not infl amed and 
have a reasonable life expectancy. In this respect, analysis of the survival 
curves in the 4D study is notable. The survival curves of the placebo and the 
active treatment groups start to deviate after four years follow-up, indeed sug-
gesting that differences might become evident with longer follow-up. It would 
be informative to know the state of infl ammation and nutrition of the patients 
included in 4D and its relation with mortality. At baseline 58.6 % of the included 
patients had LDL-cholesterol below 3.4 mmol/l. This is quite low and might be 
indicative of malnutrition. 
Thus, we feel that the data of the 4D study do not allow the general conclusion 
that ESRD patients do not benefi t from statin treatment. It will be important to 
select patients who will benefi t from such therapy. We propose that this selec-
tion will include patients with pre-existing cardiovascular disease and patients 
with a long life expectance (absence of infl ammation and malnutrition). Ongoing 
large randomized controlled trials such as AURORA and SHARP will hopefully 
provide some answers and allow a more precise way of decision making in this 
high risk population (37;51;53).
Oxidative stress in ESRD 
Background of oxidative stress
Since increased oxidative stress is characteristic for patients on dialysis and 
may play an important role in the progression of atherosclerosis in ESRD, we 
will discuss this topic in more detail.
Oxidative stress can be defi ned as the result of an imbalance between the pro-
duction of reactive oxygen species, free radicals, and anti-oxidant defences 
(37;54). Oxidative injury can change the function and structure of bio molecules 
like lipids, proteins, carbohydrates and nucleic acids. Oxidized lipids may be 
involved in the initiation and acceleration of atherosclerosis. Interventions 
directed at preventing lipid oxidation may have therapeutic potential. 
16 Chapter 1
24PJ67 IS1 Netrologie.indd   16 21-01-2008   08:38:15
Is oxidation present in ESRD?
In patients with CRF, the balance between pro- and anti-oxidant capacity is 
shifted towards an increased oxidative stress. The pro-oxidant effects are 
caused by factors that are characteristic for the CRF population, e.g. advanced 
age, diabetes mellitus, uremic toxins, chronic infl ammation, malnutrition and 
treatment with dialysis. Moreover, both the intra- and extracellular anti-oxidant 
capacity are decreased because of depletion of selenium, vitamin C, vitamin E 
and decreased activity of superoxide dismutase and glutathione peroxidase 
(37;55-58). 
For a long time, reliable assessment of oxidative stress in CRF has been prob-
lematic and the results of different studies were inconsistent. These inconsist-
encies were most likely caused by the lack of standardized methods to deter-
mine the level of oxidative stress. 
We assessed oxidative stress in ESRD patients with different methods (59). 
First, we measured the susceptibility of circulating LDL particles to copper-
induced oxidative stress in vitro as described by Esterbauer et al. (60). We 
observed that LDL particles of ESRD patients were not more susceptible for 
oxidation in vitro compared to matched controls. Our fi ndings are in agreement 
with the observations of other authors (61;62). Although these fi ndings argue 
against increased oxidative stress in ESRD, this in vitro assay has several draw-
backs. The test results may be infl uenced by the blood composition of unsatu-
rated fatty acids. In patients with ESRD levels of monounsaturated fatty acids 
(MUFA’s) but not poly-unsaturated fatty acids (PUFA’s) are higher than in con-
trols (61). Since MUFA’s are less susceptible to copper oxidation, the increased 
amounts of MUFA’s in ESRD might explain the measured decreased oxidizabil-
ity in these patients. Furthermore, the test is infl uenced by several factors like 
the blood temperature after collection, the storage temperature, and the levels 
of triglycerides, vitamin C and E in the blood. Moreover, the ‘oxidative’ situation 
in this in vitro assay might not be representative for the situation in vivo in the 
sub endothelial space, where the process of atherosclerosis takes place. 
We also evaluated in vivo LDL-oxidation using a more recently developed 
monoclonal antibody against oxidized LDL (ox-LDL). Using this direct assess-
ment of ox-LDL, we indeed found a higher LDL-oxidation level in patients with 
ESRD (59). Other markers have also been proposed for the assessment of oxi-
dation such as plasma F2-isoprostanes and advanced oxidation protein prod-
ucts (AOPP). Recent studies all provided evidence for increased oxidative 
stress in CRF (63-69).
Is there an association between increased oxidative stress and cardiovascular 
disease in ESRD?
Ox-LDL particles play a pivotal role in the development of atherosclerosis: 
these particles are incorporated without restriction by macrophages through 
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scavenger receptors. This promotes accelerated formation of foam cells, which 
will gradually transform and degrade into plaques, thus contributing to vascular 
stenoses (13;70-73). An environment in which enhanced oxidative stress is 
present will therefore add to the development of atherosclerosis and cardiovas-
cular disease.
In non-renal patients, Holvoet et al. showed that a high level of circulating ox-
LDL particles is a sensitive marker of coronary artery disease (66). Similar data 
were found in CRF patients. Hemodialysis patients with a positive history of 
atherosclerotic disease, have higher ox-LDL concentrations than patients with-
out a cardiovascular history (74). Shoji et al. investigated the association 
between antibodies against ox-LDL and the intima media thickness (IMT) in the 
carotid and femoral artery (75). They found that antibodies against ox-LDL were 
positively correlated with IMT of the carotid artery. The same authors described 
that the anti-ox-LDL antibody titer is an independent predictor of cardiovascu-
lar mortality in patients with ESRD (76).
Treatment of oxidative stress with vitamin E
Vitamin E refers to a group of eight, fat soluble, naturally occurring compounds, 
alpha-, beta-, gamma- and delta-tocopherol and alpha-, beta-, delta- and 
gamma-tocotrienols. Of these compounds, alpha-tocopherol has been found 
to be the most abundant and active anti-oxidant of LDL (77). Gamma-tocophe-
rol is the predominant form of vitamin E in human diets, alpha-tocopherol is the 
primary form of vitamin E supplements. 
Alpha-tocopherol acts by scavenging reactive oxygen species and singlet oxy-
gen that otherwise would attack bio molecules like lipids, proteins, sugars and 
nucleic acids (78). In the process of lipid peroxidation, lipids react by propaga-
tion of a lipid peroxyl radical so that a lipid radical and lipid hydroperoxide are 
formed. Alpha-tocopherol scavenges the lipid peroxyl radical before it attacks 
its substrate (lipids). In this reaction, the lipid peroxyl radical is neutralized to 
lipid hydroperoxide and (the neutral) alpha-tocopherol is formed into a stable 
alpha-tocopherol radical which does not propagate radical chains and lipid 
peroxides. Moreover, vitamin C can donate an electron to the alpha-tocopherol 
radical so that alpha-tocopherol can be regenerated. In this way, the weak anti-
oxidant vitamin C can enhance the anti-oxidative effects of vitamin E. 
Alpha-tocopherol scavenges the peroxyl radical about 10 times faster than the 
lipid reacts with the radical. Therefore, alpha-tocopherol prevents that lipids are 
modifi ed by peroxyl radicals.
It is generally accepted that patients with CRF and ESRD suffer from increased 
oxidative stress resulting in increased lipid peroxidation. This is one of the con-
tributing factors to the accelerated atherosclerosis in this population. 
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Himmelfarb et al studied the alpha- and gamma-tocopherol metabolism in 
patients with ESRD (79). They found that serum alpha-tocopherol levels were 
similar between hemodialysis patients and controls. However, the levels of 
serum gamma-tocopherol were higher in hemodialysis patients. This fi nding 
suggests that renal failure infl uences the gamma-tocopherol metabolism. The 
metabolites of both alpha and gamma- tocopherol, alpha- and gamma-car-
boxyhydroxychromans (CEHC), were respectively ten- and sixfold higher in 
hemodialysis patients compared to healthy subjects. These results confi rm the 
role of urinary excretion of the water-soluble metabolites of tocopherol in sub-
jects with normal renal function. 
The observation that increased oxidative stress may contribute to progressive 
atherosclerosis have stimulated searches for anti-oxidant therapies. 
It has been hypothesized that treatment with vitamin E can prevent the oxida-
tive modifi cation of LDL and in this way attenuate the development of athero-
sclerosis and cardiovascular disease. However, the results of studies on this 
subject are confl icting.
A meta-analysis of Vivekananthan et al. included 15 randomized controlled tri-
als, seven evaluating the effects of vitamin E and eight evaluating beta-carotene 
(80). The studies with vitamin E contained 81788 patients from different popula-
tions, most with normal renal function. Both primary and secondary prevention 
trials were pooled. No benefi cial effects of vitamin E were found. A similar con-
clusion was reached in an earlier meta-analysis by Asplund (81). Moreover, data 
published by Miller et al. suggested that high-dosage vitamin E supplementa-
tion might unexpectedly increase the all-cause mortality (82).
What is known about the treatment with vitamin E in patients with chronic 
renal failure and ESRD?
Many studies on surrogate endpoints with vitamin E have been performed on 
ESRD (83-88). These studies range from treatment with oral supplementation 
of vitamin E to treatment with vitamin E coated artifi cial kidneys. A problem in 
comparing and interpreting these studies is that the results are confl icting, 
probably as result of the lack of uniform methods to assess oxidative stress. 
In a post-hoc analysis of the Heart Outcome Prevention Evaluation study 
(HOPE), 993 patients with mild-to-moderate renal failure were analyzed (89). 
Primary endpoints were defi ned as the composite of myocardial infarction, 
stroke or cardiovascular death. Secondary endpoints included revasculariza-
tion, total mortality and clinical proteinuria. Treatment with 1 dd 400 IU vitamin 
E, did not result in reduction of primary nor secondary endpoints after an aver-
age follow up of 4.5 years. 
Thus far, the only RCT with vitamin E on hard clinical endpoints has been per-
formed by Boaz et al. (90). The Secondary Prevention with Antioxidants of 
Cardiovascular disease in Endstage renal disease (SPACE) showed that in 196 
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hemodialysis patients with known cardiovascular disease, supplementation 
with 800 IE/day of vitamin E reduced the risk on composite cardiovascular 
endpoints and myocardial infarction. This study suggests that vitamin E may be 
effective in patients with ESRD, and the differences with other studies could be 
explained by the higher grades of oxidative stress in ESRD. Although the results 
seem convincing, there are some caveats. Overall mortality was not infl uenced. 
Furthermore, the population in the study is somewhat different from the normal 
ESRD population as refl ected by a rather low sudden death rate. Apparently, 
the authors have included a population at low risk for non-atherosclerotic 
death. Notably, although many patients had experienced a previous myocardial 
infarction or cerebrovascular accident, less than 50% of the patients were 
treated with aspirin. Since the results of SPACE were mainly driven by the dif-
ference in myocardial infarctions it needs to be proven that similar benefi ts 
would have been obtained if all patients had received aspirin. Therefore, 
although the results of the SPACE study are very appealing they should be 
confi rmed in a new study with non-composite cardiovascular endpoints. 
Conclusions
Cardiovascular risk is increased in patients with CRF, and is particularly high in 
patients with ESRD. However, in patients with ESRD cardiovascular mortality is 
not primarily the consequence of classical coronary heart disease but more 
often caused by sudden cardiac death. The latter is likely related to rhythm 
disturbances due to cardiac fi brosis and hypertrophy. In patients with CRF both 
traditional cardiovascular risk factors such as hypertension, diabetes mellitus, 
smoking, hypercholesterolemia and so called non-traditional risk factors such 
as increased oxidative stress, malnutrition, disturbed calcium-phosphate bal-
ance and hyperparathyroidism contribute to the increased risk.
Although cholesterol lowering treatment is generally effective in patients with 
increased cardiovascular risk, the evidence is lacking in patients with ESRD. 
The absence of proof should not lead to therapeutic nihilism. Interpretation of 
the data is hampered by reverse epidemiology in patients with ESRD, the high 
mortality rate due to non-atherosclerotic disease and malnutrition and infl am-
mation. We would argue that cholesterol lowering should be considered in 
patients with known cardiovascular disease and patients with ESRD without 
evidence of malnutrition and infl ammation and a life expectancy > 5 years. 
Obviously, apart from cholesterol, treatment in patients with ESRD should be 
directed at optimizing all other risk factors such as hypertension, calcium-phos-
phate balance, vitamin D and hyperparathyroidism. The role of infl uencing 
altered lipids in ESRD is unclear. 
Randomized controlled trials that are underway hopefully will assist in further 
defi ning the population at risk who will benefi t from interventions directed at cho-
lesterol. In the meanwhile, treatment of patients with ESRD should be multi-
targeted. Also in this population cholesterol should not be an overlooked target.
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Outline of this thesis
In a cross-sectional study we investigated lipid profi les and the level of oxida-
tive stress in non-diabetic patients with ESRD just prior to the start of dialysis 
therapy and compared this to controls with a normal renal function (chapter 2). 
Various methods were used for the assessment of oxidative stress. We com-
pared both in vitro and in vivo measures: plasma lipid peroxides, circulating 
oxidized LDL-particles (ox-LDL), and copper-induced LDL-oxidation lag time.
In a subsequent study patients with ESRD who started dialysis treatment were 
followed for six months. At baseline and during hemodialysis treatment we 
measured lipid profi le, oxidative stress and parameters of chronic infl ammation. 
Again, oxidative stress was assessed through measurement of plasma lipid 
peroxides, circulating oxidized LDL-particles, and copper-induced LDL-oxida-
tion lag time. Furthermore, we compared effects of various treatment modalities 
(i.e. hemodialysis and peritoneal dialysis) on the mentioned study parameters. 
The results are presented in chapter 3. 
In an intervention study, we performed a single-blind randomized controlled 
trial in patients with ESRD on hemodialysis comparing two HMG-CoA reduct-
ase inhibitors (atorvastatin and simvastatin). Outcome parameters were lipid 
concentrations, lipoproteins, LDL particle heterogeneity, high sensitive-CRP, 
and in vivo markers of LDL-oxidation. As markers for in vivo LDL-oxidation, 
plasma ox-LDL concentration and IgM- and IgG-autoantibodies against ox-LDL 
were measured (chapter 4). 
In view of the potential deleterious role of oxidative stress in patients with 
ESRD, we evaluated the effect of the anti-oxidant vitamin E in a double-blind 
randomized controlled trial. Patients were treated with atorvastatin or vitamin E 
with placebo, the combination of the two active drugs or double placebo for a 
period of 12 weeks. Outcome parameters were lipid profi le, concentration of 
ox-LDL, and copper-induced LDL-oxidation lag time. Data are presented in 
chapter 5. 
The summary and main conclusions of this thesis are provided in chapter 6. 
General introduction and outline of the thesis 21
24PJ67 IS1 Netrologie.indd   21 21-01-2008   08:38:16
22 Chapter ?
24PJ67 IS1 Netrologie.indd   22 21-01-2008   08:38:16
References
1 Manjunath G, Tighiouart H, Ibrahim H, Macleod B, Salem DN, Griffi th JL et 
al. Level of kidney function as a risk factor for atherosclerotic cardiovascu-
lar outcomes in the community. J Am Coll Cardiol 2003 January 1;41(1):
47-55.
2 Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffi th JL et 
al. Level of kidney function as a risk factor for cardiovascular outcomes in 
the elderly. Kidney Int 2003 March;63(3):1121-9.
3 Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL et 
al. Kidney disease as a risk factor for development of cardiovascular dis-
ease: a statement from the American Heart Association Councils on Kidney 
in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiol-
ogy, and Epidemiology and Prevention. Circulation 2003 October 28; 
108(17):2154-69.
4 Randomised trial of cholesterol lowering in 4444 patients with coronary 
heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 
1994 November 19;344(8934):1383-9.
5 Prevention of cardiovascular events and death with pravastatin in patients 
with coronary heart disease and a broad range of initial cholesterol levels. 
The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) 
Study Group. N Engl J Med 1998 November 5;339(19):1349-57.
6 MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin 
in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lan-
cet 2002 July 6;360(9326):7-22.
7 Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG et al. 
The effect of pravastatin on coronary events after myocardial infarction in 
patients with average cholesterol levels. Cholesterol and Recurrent Events 
Trial investigators. N Engl J Med 1996 October 3;335(14):1001-9.
8 Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfi eld M et al. 
Prevention of coronary and stroke events with atorvastatin in hypertensive 
patients who have average or lower-than-average cholesterol concentra-
tions, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering 
Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs 2004;
64 Suppl 2:43-60.
9 Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW et 
al. Prevention of coronary heart disease with pravastatin in men with hyper-
cholesterolemia. 1995. Atheroscler Suppl 2004 October;5(3):91-7.
10 Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a 
signifi cant predictor of death in a cohort of chronic hemodialysis patients. 
Kidney Int 2002 May;61(5):1887-93.
General introduction and outline of the thesis 23
24PJ67 IS1 Netrologie.indd   23 21-01-2008   08:38:16
11 Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive 
value of commonly measured variables and an evaluation of death rate dif-
ferences between facilities. Am J Kidney Dis 1990 May;15(5):458-82.
12 Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G et al. Atorvas-
tatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N 
Engl J Med 2005 July 21;353(3):238-48.
13 Ross R. Atherosclerosis: an infl ammatory disease. N Engl J Med 1999 
January 14;340(2):115-26.
14 St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP 
et al. Low-density lipoprotein subfractions and the long-term risk of 
ischemic heart disease in men: 13-year follow-up data from the Quebec 
Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005 March;25(3):
553-9.
15 Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease 
in chronic renal disease. J Am Soc Nephrol 1998 December;9(12 Suppl):
S16-S23.
16 Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocar-
dial infarction among patients on long-term dialysis. N Engl J Med 1998 
September 17;339(12):799-805.
17 Landray MJ, Thambyrajah J, McGlynn FJ, Jones HJ, Baigent C, Kendall 
MJ et al. Epidemiological evaluation of known and suspected cardiovascu-
lar risk factors in chronic renal impairment. Am J Kidney Dis 2001 Septem-
ber;38(3):537-46.
18 Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricu-
lar hypertrophy in the predialysis population: identifying opportunities for 
intervention. Am J Kidney Dis 1996 March;27(3):347-54.
19 Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D et al. 
Left ventricular mass index increase in early renal disease: impact of 
decline in hemoglobin. Am J Kidney Dis 1999 July;34(1):125-34.
20 Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insuffi ciency as a 
predictor of cardiovascular outcomes and the impact of ramipril: the HOPE 
randomized trial. Ann Intern Med 2001 April 17;134(8):629-36.
21 scamps-Latscha B, Witko-Sarsat V, Nguyen-Khoa T, Nguyen AT, Gausson 
V, Mothu N et al. Advanced oxidation protein products as risk factors for 
atherosclerotic cardiovascular events in nondiabetic predialysis patients. 
Am J Kidney Dis 2005 January;45(1):39-47.
22 London GM, Parfrey PS. Cardiac disease in chronic uremia: pathogenesis. 
Adv Ren Replace Ther 1997 July;4(3):194-211.
23 Schwarz U, Buzello M, Ritz E, Stein G, Raabe G, Wiest G et al. Morphol-
ogy of coronary atherosclerotic lesions in patients with end-stage renal 
failure. Nephrol Dial Transplant 2000 February;15(2):218-23.
24 Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in 
chronic renal failure. J Am Soc Nephrol 1999 July;10(7):1606-15.
24 Chapter 1
24PJ67 IS1 Netrologie.indd   24 21-01-2008   08:38:16
25 Bethesda M., U.S.Renal Data System U2ADR. Atlas of End-Stage Renal 
Disease in the United States, National Institute of Diabetes and Digestive 
and Kidney Diseases. 2005.
26 Longenecker JC, Coresh J, Powe NR, Levey AS, Fink NE, Martin A et al. 
Traditional cardiovascular disease risk factors in dialysis patients com-
pared with the general population: the CHOICE Study. J Am Soc Nephrol 
2002 July;13(7):1918-27.
27 Baigent C, Burbury K, Wheeler D. Premature cardiovascular disease in 
chronic renal failure. Lancet 2000 July 8;356(9224):147-52.
28 Kasiske BL. Hyperlipidemia in patients with chronic renal disease. Am 
J Kidney Dis 1998 November;32(5 Suppl 3):S142-S156.
29 Quaschning T, Krane V, Metzger T, Wanner C. Abnormalities in uremic lipo-
protein metabolism and its impact on cardiovascular disease. Am J Kidney 
Dis 2001 October;38(4 Suppl 1):S14-S19.
30 Shoji T, Ishimura E, Inaba M, Tabata T, Nishizawa Y. Atherogenic lipopro-
teins in end-stage renal disease. Am J Kidney Dis 2001 October;38(4 Suppl 
1):S30-S33.
31 Tamashiro M, Iseki K, Sunagawa O, Inoue T, Higa S, Afuso H et al. Signifi -
cant association between the progression of coronary artery calcifi cation 
and dyslipidemia in patients on chronic hemodialysis. Am J Kidney Dis 
2001 July;38(1):64-9.
32 Stompor T, Rajzer M, Pasowicz M, Krasniak A, Sulowicz W, Kawecka-Jas-
zcz K et al. Coronary artery calcifi cation, common carotid artery intima-
media thickness and aortic pulse wave velocity in patients on peritoneal 
dialysis. Int J Artif Organs 2006 August;29(8):736-44.
33 Avram MM, Bonomini LV, Sreedhara R, Mittman N. Predictive value of 
nutritional markers (albumin, creatinine, cholesterol, and hematocrit) for 
patients on dialysis for up to 30 years. Am J Kidney Dis 1996 Decem-
ber;28(6):910-7.
34 Fleischmann EH, Bower JD, Salahudeen AK. Risk factor paradox in hemo-
dialysis: better nutrition as a partial explanation. ASAIO J 2001 Janu-
ary;47(1):74-81.
35 Hocher B, Ziebig R, Altermann C, Krause R, Asmus G, Richter CM et al. 
Different impact of biomarkers as mortality predictors among diabetic and 
nondiabetic patients undergoing hemodialysis. J Am Soc Nephrol 2003 
September;14(9):2329-37.
36 Nishizawa Y, Shoji T, Ishimura E, Inaba M, Morii H. Paradox of risk factors 
for cardiovascular mortality in uremia: is a higher cholesterol level better for 
atherosclerosis in uremia? Am J Kidney Dis 2001 October;38(4 Suppl 1):
S4-S7.
37 Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE et al. Asso-
ciation between cholesterol level and mortality in dialysis patients: role of 
infl ammation and malnutrition. JAMA 2004 January 28;291(4):451-9.
General introduction and outline of the thesis 25
24PJ67 IS1 Netrologie.indd   25 21-01-2008   08:38:16
38 Shoji T, Nishizawa Y, Kawagishi T, Kawasaki K, Taniwaki H, Tabata T et al. 
Intermediate-density lipoprotein as an independent risk factor for aortic 
atherosclerosis in hemodialysis patients. J Am Soc Nephrol 1998 July;9(7): 
1277-84.
39 Cressman MD, Heyka RJ, Paganini EP, O’Neil J, Skibinski CI, Hoff HF. 
Lipoprotein(a) is an independent risk factor for cardiovascular disease in 
hemodialysis patients. Circulation 1992 August;86(2):475-82.
40 Fujisawa M, Haramaki R, Miyazaki H, Imaizumi T, Okuda S. Role of lipopro-
tein (a) and TGF-beta 1 in atherosclerosis of hemodialysis patients. J Am 
Soc Nephrol 2000 October;11(10):1889-95.
41 Koda Y, Nishi S, Suzuki M, Hirasawa Y. Lipoprotein(a) is a predictor for 
cardiovascular mortality of hemodialysis patients. Kidney Int Suppl 1999 
July;71:S251-S253.
42 Longenecker JC, Klag MJ, Marcovina SM, Liu YM, Jaar BG, Powe NR et 
al. High lipoprotein(a) levels and small apolipoprotein(a) size prospectively 
predict cardiovascular events in dialysis patients. J Am Soc Nephrol 2005 
June;16(6):1794-802.
43 Tonelli M, Isles C, Curhan GC, Tonkin A, Pfeffer MA, Shepherd J et al. Effect 
of pravastatin on cardiovascular events in people with chronic kidney dis-
ease. Circulation 2004 September 21;110(12):1557-63.
44 Tonelli M, Keech A, Shepherd J, Sacks F, Tonkin A, Packard C et al. Effect 
of pravastatin in people with diabetes and chronic kidney disease. J Am 
Soc Nephrol 2005 December;16(12):3748-54.
45 Navaneethan SD, Shrivastava R. HMG CoA reductase inhibitors (statins) 
for dialysis patients. Cochrane Database Syst Rev 2004;(4):CD004289.
46 Achenbach S, Ropers D, Pohle K, Leber A, Thilo C, Knez A et al. Infl uence 
of lipid-lowering therapy on the progression of coronary artery calcifi cation: 
a prospective evaluation. Circulation 2002 August 27;106(9):1077-82.
47 Mason NA, Bailie GR, Satayathum S, Bragg-Gresham JL, Akiba T, Akizawa 
T et al. HMG-coenzyme a reductase inhibitor use is associated with mor-
tality reduction in hemodialysis patients. Am J Kidney Dis 2005 Janu-
ary;45(1):119-26.
48 Seliger SL, Weiss NS, Gillen DL, Kestenbaum B, Ball A, Sherrard DJ et al. 
HMG-CoA reductase inhibitors are associated with reduced mortality in 
ESRD patients. Kidney Int 2002 January;61(1):297-304.
49 Baigent C, Landray M, Leaper C, Altmann P, Armitage J, Baxter A et al. 
First United Kingdom Heart and Renal Protection (UK-HARP-I) study: bio-
chemical effi cacy and safety of simvastatin and safety of low-dose aspirin 
in chronic kidney disease. Am J Kidney Dis 2005 March;45(3):473-84.
50 Landray M, Baigent C, Leaper C, Adu D, Altmann P, Armitage J et al. The 
second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: 
a randomized controlled study of the biochemical safety and effi cacy of 
adding ezetimibe to simvastatin as initial therapy among patients with 
CKD. Am J Kidney Dis 2006 March;47(3):385-95.
26 Chapter 1
24PJ67 IS1 Netrologie.indd   26 21-01-2008   08:38:16
51 Fellstrom B, Zannad F, Schmieder R, Holdaas H, Jardine A, Rose H et al. 
Effect of rosuvastatin on outcomes in chronic haemodialysis patients - 
design and rationale of the AURORA study. Curr Control Trials Cardiovasc 
Med 2005 May 23;6(1):9.
52 Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. 
Effi cacy and safety of cholesterol-lowering treatment: prospective meta-
analysis of data from 90,056 participants in 14 randomised trials of statins. 
Lancet 2005 October 8;366(9493):1267-78.
53 Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kid-
ney Int Suppl 2003 May;(84):S207-S210.
54 Halliwell B. Free radicals, antioxidants, and human disease: curiosity, 
cause, or consequence? Lancet 1994 September 10;344(8924):721-4.
55 Canaud B, Cristol J, Morena M, Leray-Moragues H, Bosc J, Vaussenat F. 
Imbalance of oxidants and antioxidants in haemodialysis patients. Blood 
Purif 1999;17(2-3):99-106.
56 Galli F, Canestrari F, Bellomo G. Pathophysiology of the oxidative stress 
and its implication in uremia and dialysis. Contrib Nephrol 1999;127:1-31.
57 Galli F, Ronco C. Oxidant stress in hemodialysis. Nephron 2000 Janu-
ary;84(1):1-5.
58 Tetta C, Biasioli S, Schiavon R, Inguaggiato P, David S, Panichi V et al. An 
overview of haemodialysis and oxidant stress. Blood Purif 1999;17(2-
3):118-26.
59 Diepeveen SH, Verhoeven GH, van der PJ, Dikkeschei BL, Van Tits LJ, 
Kolsters G et al. Oxidative stress in patients with end-stage renal disease 
prior to the start of renal replacement therapy. Nephron Clin Pract 
2004;98(1):c3-c7.
60 Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of 
in vitro oxidation of human low density lipoprotein. Free Radic Res Com-
mun 1989;6(1):67-75.
61 Loughrey CM, Young IS, McEneny J, McDowell IF, McMaster C, McNamee 
PT et al. Oxidation of low density lipoprotein in patients on regular haemo-
dialysis. Atherosclerosis 1994 October;110(2):185-93.
62 Westhuyzen J, Saltissi D, Healy H. Oxidation of low density lipoprotein in 
hemodialysis patients: effect of dialysis and comparison with matched 
controls. Atherosclerosis 1997 March 21;129(2):199-205.
63 Annuk M, Fellstrom B, Akerblom O, Zilmer K, Vihalemm T, Zilmer M. Oxida-
tive stress markers in pre-uremic patients. Clin Nephrol 2001 Octo-
ber;56(4):308-14.
64 Annuk M, Soveri I, Zilmer M, Lind L, Hulthe J, Fellstrom B. Endothelial func-
tion, CRP and oxidative stress in chronic kidney disease. J Nephrol 2005 
November;18(6):721-6.
65 Handelman GJ, Walter MF, Adhikarla R, Gross J, Dallal GE, Levin NW et al. 
Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. 
Kidney Int 2001 May;59(5):1960-6.
General introduction and outline of the thesis 27
24PJ67 IS1 Netrologie.indd   27 21-01-2008   08:38:16
66 Holvoet P, Mertens A, Verhamme P, Bogaerts K, Beyens G, Verhaeghe R et 
al. Circulating oxidized LDL is a useful marker for identifying patients with 
coronary artery disease. Arterioscler Thromb Vasc Biol 2001 May;21(5):
844-8.
67 Maggi E, Bellazzi R, Gazo A, Seccia M, Bellomo G. Autoantibodies against 
oxidatively-modifi ed LDL in uremic patients undergoing dialysis. Kidney Int 
1994 September;46(3):869-76.
68 Massy ZA, Nguyen-Khoa T. Oxidative stress and chronic renal failure: 
markers and management. J Nephrol 2002 July;15(4):336-41.
69 Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, Nguyen-Khoa T, 
Nguyen AT, Zingraff J et al. Advanced oxidation protein products as a novel 
marker of oxidative stress in uremia. Kidney Int 1996 May;49(5):1304-13.
70 Galle J, Wanner C. Oxidative stress and vascular injury--relevant for 
atherogenesis in uraemic patients? Nephrol Dial Transplant 1997 Decem-
ber;12(12):2480-3.
71 Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM. The elephant in uremia: 
oxidant stress as a unifying concept of cardiovascular disease in uremia. 
Kidney Int 2002 November;62(5):1524-38.
72 Mathur S, Devaraj S, Jialal I. Accelerated atherosclerosis, dyslipidemia, 
and oxidative stress in end-stage renal disease. Curr Opin Nephrol Hyper-
tens 2002 March;11(2):141-7.
73 Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet 1994 Sep-
tember 17;344(8925):793-5.
74 Takenaka T, Takahashi K, Kobayashi T, Oshima E, Iwasaki S, Suzuki H. 
Oxidized low density lipoprotein (Ox-LDL) as a marker of atherosclerosis in 
hemodialysis (HD) patients. Clin Nephrol 2002 July;58(1):33-7.
75 Shoji T, Kimoto E, Shinohara K, Emoto M, Ishimura E, Miki T et al. The 
association of antibodies against oxidized low-density lipoprotein with 
atherosclerosis in hemodialysis patients. Kidney Int Suppl 2003 May;(84):
S128-S130.
76 Shoji T, Fukumoto M, Kimoto E, Shinohara K, Emoto M, Tahara H et al. 
Antibody to oxidized low-density lipoprotein and cardiovascular mortality 
in end-stage renal disease. Kidney Int 2002 December;62(6):2230-7.
77 Esterbauer H, Puhl H, Waeg G, Krebs A, Tatzber F, Rabl H. Vitamin E and 
atherosclerosis: an overview. J Nutr Sci Vitaminol (Tokyo) 1992;Spec 
No:177-82.
78 Kaiser S, Di MP, Murphy ME, Sies H. Physical and chemical scavenging of 
singlet molecular oxygen by tocopherols. Arch Biochem Biophys 1990 
February 15;277(1):101-8.
79 Himmelfarb J, Kane J, McMonagle E, Zaltas E, Bobzin S, Boddupalli S et 
al. Alpha and gamma tocopherol metabolism in healthy subjects and 
patients with end-stage renal disease. Kidney Int 2003 September;64(3):
978-91.
28 Chapter 1
24PJ67 IS1 Netrologie.indd   28 21-01-2008   08:38:17
80 Vivekananthan DP, Penn MS, Sapp SK, Hsu A, Topol EJ. Use of antioxidant 
vitamins for the prevention of cardiovascular disease: meta-analysis of 
randomised trials. Lancet 2003 June 14;361(9374):2017-23.
81 Asplund K. Antioxidant vitamins in the prevention of cardiovascular dis-
ease: a systematic review. J Intern Med 2002 May;251(5):372-92.
82 Miller ER, III, Pastor-Barriuso R, Dalal D, Riemersma RA, Appel LJ, Guallar 
E. Meta-analysis: high-dosage vitamin E supplementation may increase 
all-cause mortality. Ann Intern Med 2005 January 4;142(1):37-46.
83 Badiou S, Cristol JP, Morena M, Bosc JY, Carbonneau MA, Dupuy AM et 
al. Vitamin E supplementation increases LDL resistance to ex vivo oxida-
tion in hemodialysis patients. Int J Vitam Nutr Res 2003 July;73(4):290-6.
84 Diepeveen SH, Verhoeven GW, van der PJ, Dikkeschei LD, Van Tits LJ, 
Kolsters G et al. Effects of atorvastatin and vitamin E on lipoproteins and 
oxidative stress in dialysis patients: a randomised-controlled trial. J Intern 
Med 2005 May;257(5):438-45.
85 Giray B, Kan E, Bali M, Hincal F, Basaran N. The effect of vitamin E sup-
plementation on antioxidant enzyme activities and lipid peroxidation levels 
in hemodialysis patients. Clin Chim Acta 2003 December;338(1-2):91-8.
86 Kobayashi S, Moriya H, Aso K, Ohtake T. Vitamin E-bonded hemodialyzer 
improves atherosclerosis associated with a rheological improvement of 
circulating red blood cells. Kidney Int 2003 May;63(5):1881-7.
87 Morimoto H, Nakao K, Fukuoka K, Sarai A, Yano A, Kihara T et al. Long-
term use of vitamin E-coated polysulfone membrane reduces oxidative 
stress markers in haemodialysis patients. Nephrol Dial Transplant 2005 
December;20(12):2775-82.
88 Ohkawa S, Yoneyama T, Shimoi K, Takita T, Maruyama Y, Kumagai H. Pro-
oxidative effect of alpha-tocopherol in the oxidation of LDL isolated from 
co-antioxidant-depleted non-diabetic hemodialysis patients. Atherosclero-
sis 2004 October;176(2):411-8.
89 Mann JF, Lonn EM, Yi Q, Gerstein HC, Hoogwerf BJ, Pogue J et al. Effects 
of vitamin E on cardiovascular outcomes in people with mild-to-moderate 
renal insuffi ciency: results of the HOPE study. Kidney Int 2004 April;65(4): 
1375-80.
90 Boaz M, Smetana S, Weinstein T, Matas Z, Gafter U, Iaina A et al. Second-
ary prevention with antioxidants of cardiovascular disease in endstage 
renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000 
October 7;356(9237):1213-8.
General introduction and outline of the thesis 29
24PJ67 IS1 Netrologie.indd   29 21-01-2008   08:38:17
30 Chapter ?
24PJ67 IS1 Netrologie.indd   30 21-01-2008   08:38:17
C
ha
p
te
r
2
Oxidative stress in patients with end-stage renal 
disease prior to the start of renal replacement 
therapy.
Sabine H.A. Diepeveen
Gertie H.W.E. Smeets
Job van der Palen 
Bert (L).D. Dikkeschei
Berry (L).J.H. van Tits 
Geert Kolsters 
Joop J.G. Offerman 
Henk J.G. Bilo 
Anton F.H. Stalenhoef 
Nephron Clinical Practice 2004; 98:c3-7
24PJ67 IS1 Netrologie.indd   31 21-01-2008   08:38:17
32 Chapter ?
24PJ67 IS1 Netrologie.indd   32 21-01-2008   08:38:17
Abstract
Background
In patients with end-stage renal disease (ESRD), cardiovascular complications 
are the main cause of death. Increased oxidative stress is one of the risk factors 
for enhanced atherosclerosis in this population. Literature data vary partially 
dependent on differences in methodology. The present study compares three 
different methods: plasma lipid peroxides, the newly developed measurement 
of circulating oxidized-LDL particles and the frequently used copper-induced 
LDL-oxidation lag time. 
Methods
We assessed plasma lipid peroxides, circulating oxidized-LDL particles and in 
vitro copper-induced LDL-oxidation lag time in 47 non-diabetic patients with 
ESRD, at the start of renal replacement therapy, and compared these with 41 
age- and sex-matched controls. 
Results
In ESRD, total cholesterol (4.6 ± 1.1 vs. 5.6 ± 0.9 mmol/l; p<0.001), LDL-cho-
lesterol (2.8 ± 0.8 vs. 3.5 ± 0.7 mmol/l; p<0.001) and HDL-cholesterol (1.0 ± 0.3 
vs. 1.4 ± 0.4 mmol/l; p<0.001) were lower compared to controls. Plasma lipid 
peroxides were higher (1.1 ± 0.5 vs. 0.8 ± 0.5 µmol/l; p=0.003) in ESRD. No 
differences were observed in plasma ox-LDL (63.1 ± 62.0 vs. 55.3 ± 48.0 mg/l). 
However, due to the lower plasma LDL-cholesterol in ESRD, LDL-oxidation 
level was increased in ESRD (7.1 ± 0.1 vs. 4.2 ± 0.3%; p=0.03). LDL lag time 
was slightly longer (89 ± 11 vs. 84 ± 11 min; p=0.04) in ESRD. There were no 
signifi cant differences regarding the amount and rate of dienes produced. 
Conclusions
Elevated levels of lipid peroxides and higher LDL-oxidation levels support the 
theory that ESRD is associated with increased oxidative stress, which may 
explain the accelerated atherosclerosis. The measured amount of oxidative 
stress is not refl ected by in vitro oxidizability of LDL.
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Introduction
Enhanced atherosclerosis and consequent cardiovascular disease are major 
clinical problems in patients with end-stage renal disease (ESRD). The cardio-
vascular mortality rate in this population is about 9% per year, which is 30 times 
the risk in the general population (1). Besides common risk factors such as 
hypertension, diabetes mellitus and smoking, uremia- and dialysis-related risk 
factors are involved in the development and progression of atherosclerosis in 
this patient group. Furthermore, dyslipidemia, prothrombotic factors, hyperho-
mocysteinemia, malnutrition and chronic infl ammatory state are more prevalent 
in ESRD and contribute to cardiovascular disease. Oxidative stress is often 
associated with these risk factors and related to atherosclerosis (2;3). 
Oxidized low-density lipoprotein (ox-LDL) is considered to be highly athero-
genic. LDL seems to be more rapidly oxidized in ESRD than in subjects with a 
normal renal function (4;5). However, data of studies on oxidative stress in 
ESRD are not consistent: several studies showed increased oxidative stress 
(3;6;7) whereas others did not, or even showed a decrease in oxidative stress 
(8-11). These inconsistencies are most likely caused by the lack of a standard-
ized method to determine free radical activity. Indirect indicators of free radical 
activity, such as products of lipid, DNA and protein oxidation or serum antioxi-
dant activity are often used as a measure for oxidative stress (12). A copper-
induced, kinetic LDL-oxidation assay, described by Esterbauer et al. (13) has 
also previously been used to determine the susceptibility of circulating LDL to 
oxidative modifi cation in high-risk populations. More recently, the development 
of monoclonal antibodies to epitopes of ox-LDL made it possible to determine 
directly the amount of ox-LDL particles present in the circulation (14). An 
increased amount of ox-LDL has been associated with the presence of athero-
sclerosis (3;15). In this study we assessed this newly developed monoclonal 
antibody, a promising marker of atherosclerosis as well as some parameters 
commonly used by us and others before, in a group of patients with ESRD, not 
yet treated with renal replacement therapy.
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Methods
Population 
Non-diabetic patients diagnosed with ESRD at the Department of Nephrology 
of the Isala Clinics, location Weezenlanden, were asked to participate in this 
study. Patients and controls with similar age, sex distribution and smoking hab-
its were studied after informed consent. Both the scientifi c committee of the 
Department of Internal Medicine and the hospital’s Medical Ethical Committee 
approved the study.
Laboratory Measurements
Just prior to the fi rst session of renal replacement therapy and after a light meal, 
venous blood was collected in EDTA Vacutainer® tubes (Becton Dickinson). The 
blood samples were immediately placed on ice, and plasma was obtained by 
centrifugation at 4°C (3,000 rpm) within 30 min. Plasma, supplemented with 
saccharose (0.6%, w/v) as a cryoprotectant, was frozen on liquid nitrogen and 
stored at -80°C until analysis.
Plasma total cholesterol, high-density lipoprotein cholesterol (HDL), triglycer-
ides, glucose, creatinine, blood urea nitrogen (BUN) and uric acid were meas-
ured on a Hitachi 917 analyzer using Roche reagents (Roche, Mannheim, Ger-
many). Low-density lipoprotein cholesterol (LDL) was calculated using the 
Friedewald formula. Vitamin E was determined with reversed-phase HPLC 
(BAS-200B and Jasco PU-980) equipped with fl uorescence detection using a 
commercially available test kit (195.4075; BioRad, Calif., USA).
Lipid peroxide metabolites were measured with the LPO-586 kit (Bioxytech, 
Cat. No. 21012D; Oxis International Inc., Portland, Oreg., USA).
After thawing of the plasma sample, LDL was isolated by density-gradient ultra-
centrifugation (40,000 rpm in a SW40 rotor for 18 h at 4°C; Beckman, Palo Alto, 
Calif., USA). The protein content of the LDL fraction was measured and LDL-
oxidation assays were performed as described by Esterbauer et al. (13) as 
modifi ed by Princen et al. (16). Briefl y, the oxidation of LDL (60 µg apolipopro-
tein/ml) was initiated by the addition of CuSO4 (fi nal concentration of 18 µM) at 
37°C. The kinetics of the oxidation of LDL was determined by monitoring the 
change of the 234-nm diene absorption in a water-thermostated UV spectro-
photometer (Lambda 12; Perkin Elmer, GmbH, Germany), equipped with an 8-
position automatic row-sampler changer. Each LDL preparation was oxidized 
twice, in two separate oxidation runs on the same day. Every oxidation run was 
controlled by analyzing one reference LDL, freshly prepared from pooled plas-
ma stored with 6 g/l saccharose at -80°C. The oxidation parameter lag time was 
calculated as described previously (17).
Ox-LDL was measured by a sandwich enzyme-linked immunosorbent assay 
(ELISA) method using the monoclonal antibody 4E6 (developed by Dr. Holvoet 
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from the Center for Experimental Surgery and Anesthesiology, Catholic Univer-
sity of Leuven, Leuven, Belgium; purchased from Mercodia, Uppsala, Sweden) 
as the capture antibody and anti-human apoB-100 polyclonal antibody for 
detection (18).
Statistical Analysis
Statistical analysis was performed using SPSS 10.0 for Windows. Values are 
expressed as means ± SD. The Wilcoxon rank sum test was used to compare the 
patients with controls; p-values ≤ 0.05 were considered statistically signifi cant.
Results
Population
Forty-seven patients with ESRD were included in this study and they were 
compared to 41 controls. The baseline characteristics of patients and controls 
are listed in table 1. The body mass index in patients was lower than in controls. 
No medication was used in the control group. The medication used in the ESRD 
group is described in table 1.
Table 1.  Baseline characteristics and medication of ESRD patients and controls
ESRD (n = 47 ) Controls (n = 41) p-value 
a male: female 33:14 30:11 n.s.
b age, years 55 (17) 56 (18) n.s.
a current smoker 12 15 n.s.
b body mass index, kg/m2 24.2 (3.7) 26.3 (4.1) 0.01
a Antihypertensive drugs
   diuretic
   ß-Blocker
   ACE-inhibitor
   calcium-antagonist
20
21
21 
19
10
10
10 
10
a  Lipid-lowering drugs
   statin 18a 10a
a Vitamins
   vitamin C
   multivitamins
18a
10a
10a 
10a
a  values presented as numbers
b values presented as mean ± standard deviation
Table 2 shows routine parameters of patients and controls. Although diabetic 
patients were excluded, (non-fasting) glucose was higher in the ESRD group. 
Creatinine, BUN and uric acid were signifi cantly increased in ESRD. Plasma 
total cholesterol, HDL- and LDL-cholesterol were lower and triglycerides were 
higher in patients with ESRD compared to controls (table 2).
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Table 2 Routine parameters of ESRD patients and controls
a Parameter ESRD (n = 47) Controls (n = 41) p-value 
creatinine (µmol/l) 805 ± 335 90 ± 10 <0.001
BUN (mmol/l) 38 ±10 5.5 ±1.3 <0.001
uric acid (mmol/l) 0.5 ± 0.1 0.3 ± 0.7 <0.001
glucose (mmol/l) 6.7 ± 1.6 5.8 ± 1.3 0.001
total cholesterol (mmol/l 4.6 ± 1.1 5.6 ± 0.9 <0.001
LDL-cholesterol (mmol/l) 2.8 ± 0.8 3.5 ± 0.7 <0.001
HDL-cholesterol (mmol/l) 1.0 ± 0.3 1.4 ± 0.4 <0.001
triglycerides (mmol/l) 2.2 ± 1.2 1.6 ± 0.9 0.002
a values presented as means ± standard deviation
Oxidation Parameters and Plasma Vitamin E
The lag time of in vitro LDL-oxidation was slightly longer in ESRD than in con-
trols. There were no signifi cant differences regarding amount and rate of dienes 
produced (table 3). Plasma lipid peroxides were signifi cantly higher in ESRD. 
The concentrations of circulating ox-LDL did not differ between both groups, 
but due to the signifi cant lower LDL-cholesterol in ESRD, the LDL-oxidation 
level was higher in ESRD than in controls (table 3). Plasma level of vitamin E 
was higher in ESRD than in controls (table 3).
Table 3  Plasma vitamin E, LDL oxidizability, oxidized LDL and plasma lipid peroxides of ESRD 
patients and controls
a Parameter ESRD (n = 47) Controls (n = 41) p-value 
vitamin E (IU/l) 1393 ± 369 1226 ± 329 0.02
lag time (min) 89 ± 11 84 ± 11 0.04
rate (nmol/min/mg LDL protein) 13.8 ± 2.2 13.9 ± 2.0 n.s.
dienes (nmol/mg LDL protein) 605 ± 64 612 ± 66 n.s.
ox-LDL (mg/l) 63.1 ± 62.0 55.3 ± 48 n.s.
ox-LDL/LDL (%) 7.1 ± 0.1 4.2 ± 0.3 0.03
lipid peroxides (µmol/l) 1.1 ± 0.5 0.8 ± 0.5 0.003
a values presented as means ± standard deviation
Discussion
In the present study in non-diabetic patients with ESRD prior to the start of 
renal replacement therapy, we observed elevated levels of lipid peroxides and 
a higher LDL-oxidation level compared to controls. Both fi ndings indicate the 
presence of increased oxidative stress in ESRD. On the other hand, the oxidiz-
ability of LDL particles isolated from plasma of ESRD patients was lower com-
pared to controls.
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Previous studies showed that both dialyzed and undialyzed ESRD patients 
have higher plasma levels of lipid peroxides (6;19;20). Lipid peroxides are 
formed during the peroxidation of polyunsaturated fatty acids (PUFA’s) and can 
therefore be considered as markers of systemic oxidative stress. Selvaraj et al. 
(20) showed a correlation between lipid peroxides and protein glycation in 
undialyzed ESRD patients.
Oxidative modifi cations of proteins are considered to be good markers of oxi-
dative stress with more stability than lipids (21). When LDL is exposed to oxida-
tive stress, apolipoprotein B-100 is modifi ed. The development of monoclonal 
antibodies to epitopes of ox-LDL made it possible to determine directly the 
amount of ox-LDL particles present in the circulation (14). Levels of ox-LDL are 
associated with the presence of atherosclerosis. This has been shown in both 
renal and non-renal patients (3;14;15;18). In the present study we did not fi nd 
higher absolute levels of oxidized LDL in our population, but since LDL was 
signifi cantly lower in ESRD compared to controls, we calculated the LDL-oxida-
tion levels (ox-LDL:LDL). These were signifi cantly higher in ESRD.
The assessment of LDL oxidizability, performed by measuring the lag time of in 
vitro LDL-oxidation, revealed opposite fi ndings: we observed a slightly longer 
lag time of LDL in ESRD, indicating an increased resistance against oxidative 
stress of LDL in vitro in this population. Our fi ndings correspond with those of 
other authors (8-11;18). Several explanations have been postulated to explain 
these fi ndings: Loughrey et al. (8) showed in their ESRD population that the 
monounsaturated fatty acids (MUFA’s) and not PUFA’s in LDL were higher in 
ESRD than in controls. Since MUFA’s are less susceptible to copper oxidation 
(22;23) increased amounts of MUFA’s present in LDL of ESRD patients might 
underlie the decreased oxidizability of LDL of these patients. In CAPD patients, 
Roob et al. (9) observed no difference in LDL oxidizability nor in auto-antibody 
titers against oxidized LDL despite the higher LDL PUFA content. They explained 
their fi ndings by suggesting effi cient protection by LDL-associated lipophilic anti-
oxidants (e.g. alpha- and gamma-tocopherol). In our study we found slightly 
higher levels of vitamin E in the ESRD population. Since LDL-cholesterol was 
lower in this group, more vitamin E was available per LDL particle. In vivo how-
ever, many more factors than fatty acid composition and vitamin E content deter-
mine the susceptibility to oxidation of LDL. Due to the absence of these factors 
during in vitro oxidation, this assay may not refl ect what is happening in vivo.
In a dialysis population (24) and in a population with chronic renal failure (6) 
shorter lag times were observed compared to controls. Compared to our data, 
these inconsistent fi ndings may be explained by differences between study 
groups regarding demographic characteristics, degree of renal failure, treat-
ment with renal replacement therapy or composition of fatty acids in LDL.
Despite the absence of the hydrophilic vitamin C in the in vitro LDL-oxidation 
assay, supplementation with high-dose vitamin C can infl uence LDL oxidizabil-
ity (25). However, our patients received supplementation with only 50 mg daily; 
we consider this dose too low to be able to infl uence LDL oxidizability.
Oxidative stress in ESRD prior to dialysis 39
24PJ67 IS1 Netrologie.indd   39 21-01-2008   08:38:18
Statins (18;26) and antihypertensive drugs (27) can also infl uence the amount 
of oxidative stress. In contrast to the control group, some of our patients were 
treated with statins and/or antihypertensive drugs. Small effects of these drugs 
on in vitro LDL-oxidation cannot be excluded.
Improving the cardiovascular outcome in this population should contain strate-
gies aimed at the different risk factors for atherosclerosis. Regarding oxidative 
stress, treatment with anti-oxidants may possibly be useful (28;29) and should 
be considered in this patient population in addition to treatment with other 
drugs, e.g. statins.
Thus before the start of renal replacement therapy, ESRD patients have an 
increased LDL-oxidation level. This should be considered as one of the risk 
factors of the multifactorial process of atherosclerosis. Up to now it is unclear 
whether this is a refl ection of increased oxidative stress or of the severity of 
atherosclerosis or of a combination of both. The assessment of oxidative stress 
is diffi cult and is infl uenced by many factors. Altered lipid status, iron status, 
hyperhomocysteinemia, malnutrition and chronic infl ammation have been sug-
gested to be associated with increased oxidative stress and consequently 
enhanced atherosclerosis in ESRD populations. These factors and also the 
presence of potential anti-oxidants and anti-oxidative effects of different drugs 
should be taken into account when interpreting the results. In this respect, the 
in vitro method of measuring LDL oxidizability does not seem to be reliable and 
measurement of oxidized LDL particles is preferable.
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Abstract
Background
Disturbed lipid profi le and increased oxidative stress are recognized as two of 
the ‘non-traditional’ cardiovascular risk factors in end-stage renal disease and 
renal replacement therapy. There are very few prospective data of the infl uence 
of renal replacement therapy on these two factors. In the present study we 
investigated prospectively the effects of the initiation of both hemo- and peri-
toneal dialysis therapy on lipid profi le and parameters of LDL-oxidation.
Methods
We assessed lipid profi le, plasma lipid peroxides and in vitro copper-induced 
LDL-oxidation in 46 patients with end-stage renal disease prior to the start of 
renal replacement therapy and after six months of treatment with either hemo-
dialysis (n = 33) or peritoneal dialysis (n = 13). 
Results
After six months of treatment with hemodialysis there was an increase in total 
cholesterol (4.6 ± 1.1 vs 5.0 ± 1.3 mmol/l; p<0.05) and triglycerides (2.0 ± 0.9 
vs 2.8 ± 1.6 mmol/l; p<0.03). In the peritoneal dialysis group no differences 
were observed in the lipid profi le. Regarding lipid peroxides and in vitro copper-
induced LDL-oxidation, also no changes were observed after six months of 
treatment.
Conclusion
Dyslipidemia aggravates after six months of hemodialysis but not after six 
months of peritoneal dialysis. During this period, no net effects on oxidative 
stress could be demonstrated.
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Introduction
Like in the general population, cardiovascular disease is the main cause of 
death in patients with end-stage renal disease (ESRD) and renal replacement 
therapy. However, there is a great difference in incidence of cardiovascular 
disease between both populations: cardiovascular mortality in a dialysis popu-
lation under 45 years of age is more than 100-fold higher than in the general 
population, and in an elderly ESRD population the cardiovascular mortality 
is still fi ve-fold higher than in the general population (1). These data and the 
fact that the cardiovascular problems tend to increase as the renal function 
declines, suggest that besides the common cardiovascular risk factors like 
hypertension and diabetes mellitus, there must be additional factors in ESRD 
and renal replacement therapy which contribute to the development of cardio-
vascular disease. Studies have revealed several so called non-traditional car-
diovascular risk factors in ESRD and dialysis-populations: hyperhomocysteine-
mia, malnutrition, chronic infl ammation, enhanced oxidative stress and dyslipi-
demia are more prominent in ESRD and renal replacement therapy (2).
Oxidative stress can be defi ned as an imbalanced pro-oxidant/anti-oxidant 
ratio, in favour of the former. The disturbed metabolic state in patients with 
ESRD and the treatment with dialysis can increase the pro-oxidant state (3;4). 
The reduced anti-oxidant state in this patient group might be explained by 
diminished plasma glutathione levels (5), an increased ratio of oxidized to 
reduced thiols (6) or loss of anti-oxidant vitamins. 
In the present study we investigated the effects of the initiation of both hemo- 
and peritoneal dialysis therapy on parameters of LDL-oxidation and lipid profi le. 
Subjects and Methods
Study population
For this study at the Department of Nephrology Isala Clinics, location Weezen-
landen, we studied 46 patients with ESRD before and during the fi rst six 
months of renal replacement therapy with either hemodialysis or peritoneal 
dialysis. There was no randomization: if possible, patients were treated with the 
dialysis modality of their fi rst choice. 
Both the scientifi c committee of the Department of Internal Medicine and the 
hospital’s Medical Ethical Committee approved the study. 
Laboratory measurements
Immediately prior to the fi rst session of dialysis and after a light meal, venous 
blood was collected in EDTA Vacutainer® tubes (Becton Dickinson). The sec-
ond blood sample was taken after six months of treatment with dialysis. 
The blood samples were immediately placed on ice and plasma was obtained 
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by centrifugation at 4ºC (3000 rpm) within 30 minutes. Plasma, supplemented 
with saccharose (0.6% w/v) as a cryoprotectant, was frozen on liquid nitrogen 
and stored at -80ºC until analysis.
Plasma total cholesterol (Chol), high-density lipoprotein cholesterol (HDL), trig-
lycerides (TG), glucose, creatinin, blood urea nitrogen (BUN) and uric acid, were 
measured on a Hitachi 917 analyzer, using Roche reagents (Roche, Mannheim, 
Germany). Low-density lipoprotein cholesterol (LDL) was calculated using the 
Friedewald formula.
Vitamin E was determined with reversed-phase HPLC (BAS-200B and Jasco 
PU-980) equipped with fl uorescence detection using a commercially available 
test kit (195.4075, BioRad, CA, USA).
Lipid peroxides metabolites (LPO) were measured with the LPO-586 kit (Biox-
ytech, Oxis international Inc. (cat.no. 21012D), Portland, USA).
After thawing of the plasma sample, LDL was isolated by density-gradient ultra-
centrifugation (40,000 rpm in a SW-40 rotor for 18h at 4ºC, Beckman, Palo Alto, 
CA, USA). The protein content of the LDL fraction was measured and LDL-oxi-
dation assays were performed as described by Princen et al. (7). Briefl y, the 
oxidation of LDL (60µg apolipoprotein/ml) was initiated by the addition of CuSO4 
(fi nal concentration of 18 µM) at 37ºC. The kinetics of the oxidation of LDL were 
determined by monitoring the change of the 234 nm diene absorption in a water-
thermostated UV spectrophotometer (Lambda12, Perkin Elmer, GmBH, Ger-
many), equipped with an 8-position automatic row-sampler changer. Each LDL 
preparation was oxidized twice, in two separate oxidation runs on the same day. 
Every oxidation run was controlled by analyzing one reference LDL, freshly pre-
pared from pooled plasma stored with 6g/l saccharose at -80ºC. The oxidation 
parameter lag time was calculated as described previously (8).
Stastical analysis
Statistical analysis was performed using SPSS 11.0 for Windows. Values are 
expressed as mean ± standard deviation. The Wilcoxon Rank Sum test was 
used to compare between group differences in continuous variables while the 
chi-square test was used to compare differences in proportions. P-values equal 
to or less than 0.05 were considered statistically signifi cant.
Results
Demographic characteristics of the studied population are shown in table 1. Of 
the 46 patients, 13 were treated with peritoneal dialysis and 33 with hemodi-
alysis.
The group treated with hemodialysis was signifi cantly older than the group who 
received peritoneal dialysis treatment. Furthermore, there were almost twice as 
much diabetic patients in the hemodialysis group, but this difference did not 
reach signifi cance. Other demographic characteristics were comparable.
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Table 1. Demografi c characteristics of the study population at baseline 
HD (n=33) PD (n=13)
a Male: female 22:11 11:2
b Age (years) 62.9 (13.9) 47.5 (14.5)
a Diabetes 10 (30.3%) 2 (15.4%)
a Current smoker 7 (21.2%) 4 (30.8%)
a Cardiovascular disease 10 (30.3%) 3 (23.1%)
a Cerebrovascular disease 2 (6.1%) 0 (0%)
a values presented as numbers
b values presented as mean ± standard deviation
After six months of dialysis, the systolic blood pressure and the use of antihy-
pertensive drugs in the hemodialysis group was reduced (table 2). Whereas the 
Body Mass Index had not changed in the hemodialysis group, it increased in 
the peritoneal dialysis group.
Table 2.  Clinical variables and medication in hemo- and peritoneal dialysis patients
HD (n=33) PD (n=13)
Baseline 6 months P-value Baseline 6 months P-value
a  RR systolic 
(mmHg)
160 ± 34.4 145± 21.4 0.04 152 ± 16.8 143 ± 19.4 n.s.
a  RR diastolic    
(mmHg)
87 ± 14.9 86 ± 10.9 n.s. 93 ± 13.7 88.4 ± 5.4 n.s.
a  Body Mass Index 
(kg/m2)
24.9 ± 4.7 24.7 ± 4.3 n.s. 23.1 ± 3.2 23.8 ± 3.0 0.04
b  Vitamin C 
(1 dd 50mg)
13 (39.4%) 33 (100%) <0.01 6 (46.2%) 13 (100%) 0.08
b  Folic acid 
(1 dd 5mg)
7 (21.2%) 18 (54%) 0.02 1 (7.7%) 6 (46%) 0.03
b  Lipid lowering 
drugs
8 (24.3%) 3 (9.1%) 0.06 3 (23.1%) 3 (23.1%) n.s.
b  ≥ 1 
Antihypertensive 
drug(s)
23 (70%) 18 (55%) 0.03 12 (92%) 11 (85%) n.s.
b  ≥ 1 Phosphate-
binding drug(s)
31 (94%) 32 (97%) n.s. 13 (100%) 12 (92%) n.s.
a values presented as mean ± standard deviation
b values presented as numbers
After six months of dialysis there was a signifi cant reduction in BUN and uric 
acid in both groups. The level of hemoglobin rose in both groups, however, the 
increase in the peritoneal dialysis group did not reach signifi cance (table 3). 
Regarding the lipids, we observed an increase in the concentration of both 
plasma total cholesterol and triglycerides in the hemodialysis group. There were 
no changes in the peritoneal dialysis group.
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Table 3.  Biochemical variables in hemo- and peritoneal dialysis patients at baseline and after six 
months of dialysis therapy
HD (n=33) PD (n=13)
a Parameter Baseline 6 months P-value Baseline 6 months P-value
hemoglobin 
(mmol/l)
5.8 ± 1.1 7.3 ± 0.9 <0.01 6.7± 101 7.5± 1.4 n.s.
creatinin 
(µmol/l)
747 ± 266 812 ± 223 n.s. 789 ±377 881 ± 270 n.s.
BUN 
(mmol/l)
39.2 ± 10.7 27.2 ± 6.1 <0.01 32.4 ± 9.4 25.4 ± 2.7 0.03
uric acid 
(mmol/l)
0.42 ± 0.06 0.38 ± 0.09 <0.01 0.48 ± 0.1 0.37 ± 0.07 <0.01
glucose 
(mmol/l)
7.8 ± 2.9 6.2 ± 1.9 0.01 6.2 ± 0.9 5.8 ± 1.5 n.s.
total cholesterol 
(mmol/l)
4.6 ± 1.1 5.0 ± 1.3 0.05 5.2 ± 1.4 4.9 ± 0.8 n.s.
triglycerides 
(mmol/l)
2.0 ± 0.9 2.8 ± 1.6 0.03 2.9 ± 1.6 3.1 ± 1.9 n.s.
HDL cholesterol 
(mmol/l)
1.0 ± 0.4 0.9 ± 0.3 n.s. 0.9 ± 0.2 1.0 ± 0.4 n.s.
LDL cholesterol 
(mmol/l)
2.7 ± 0.9 2.9 ± 1.1 n.s. 3.0 ± 1.0 2.5 ± 0.5 n.s.
a values presented as mean ± standard deviation
For both groups no signifi cant changes were observed in parameters of in vitro 
LDL-oxidation, plasma lipid peroxides or plasma vitamin E (table 4).
Table 4.  Plasma vitamin E, LDL oxidizability and plasma lipid peroxides in hemo- and peritoneal 
dialysis patients at baseline and after six months of dialysis therapy
HD (n=33) PD (n=13)
a Parameter Baseline  6 months P-value Baseline 6 months P-value
vitamin E (IU/l) 1330 ± 411 1430 ± 533 n.s. 1433 (268) 1520 (318) n.s.
lag time (min) 92.6 ± 12 92.0 ± 18 n.s. 88.4 ± 13 91.1 ± 11 n.s.
rate (nmol/min/mg 
LDL protein) 
14.0 ± 2.2 14.3 ± 2.6 n.s. 14.6 ± 2.6 14.2 ± 2.0 n.s.
dienes (nmol/mg 
LDL protein)
618 ± 72 632 ± 81 n.s. 623 ± 64 612 ± 64 n.s.
lipid peroxides (µmol/l) 1.1 ± 0.6 1.2 ± 0.6 n.s. 1.2 ± 0.6 1.5 ± 0.9 n.s.
a values presented as mean ± standard deviation
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Discussion
In the present study we observed worsening of lipid profi le of ESRD patients 
after the start of hemodialysis but not peritoneal dialysis. Regarding the lipid 
peroxides and LDL-oxidizability there were no changes in both groups during 
the fi rst six months of dialysis therapy. 
The prevalence of dyslipidemia in ESRD is higher than in the general population 
and contributes to the increased cardiovascular risk of the ESRD population. 
Dyslipidemia in ESRD is characterized by reduced concentrations of apoA-con-
taining lipoproteins (HDL) and increased concentrations of triglyceride-rich 
apoB-containing lipoproteins, such as VLDL and intermediate-density lipopro-
tein (IDL). There is a preferential increase in the levels of IDL and small-dense 
LDL (9). The disturbed lipid profi le usually is already present in early stages of 
renal disease and aggravates as renal failure increases. 
The start of renal replacement therapy therapy decreases uremic symptoms, 
but its infl uence on the uremic dyslipidemia is not clear. Most data on lipid pro-
fi le in patients treated with hemo- or peritoneal dialysis are derived from cross-
sectional studies in which patients on a chronic treatment with dialysis are 
compared to healthy controls. Attman et al. found no differences in plasma total 
cholesterol and LDL-C, higher levels of triglycerides and lower HDL-C in 
patients on chronic hemodialysis compared to healthy controls (10). In a large 
cohort, Shoji et al. found lower plasma total cholesterol and higher triglycerides 
in hemodialysis patients compared with controls (11). Lee et al. studied total 
cholesterol, triglycerides, VLDL-C, LDL-C and HDL-C in 18 pre-dialysis patients 
and compared these with 8 patients on chronic hemodialysis and 10 healthy 
controls (12). They observed no differences in plasma lipids between the pre-
dialytic and the dialysis population, suggesting no infl uence of dialysis on the 
lipid profi le. The main difference between our study and the study by Lee is that 
we investigated the effect of dialysis on lipid profi le prospectively. In addition to 
the different designs (cross-sectional versus prospective) the glomerular fi ltra-
tion rate (GFR) of the pre-dialysis populations differs as well: in our study all 
patients had an immediate indication for dialysis therapy (GFR ≤ 15 ml/min/1.73 
m2) whereas the mean GFR in the study of Lee was 30.8 ± 14.6 ml/min/1.73 m2. 
The severity of renal dysfunction may co-determine the infl uence of dialysis on 
lipid profi le. In a prospective study in hemodialysis patients, Stenvinkel et al. 
observed an increase in total cholesterol and triglycerides (2). This is in agree-
ment with the present study. There are more prospective data in peritoneal 
dialysis populations. Faller and Lameire found that both total cholesterol and 
triglycerides increased during the fi rst year of treatment and declined from the 
6th year on to pre-dialysis values (13). In a prospective study by Little et al. (14), 
lipid profi le was measured every six months after initiating peritoneal dialysis. 
Already after the fi rst six months there was an increase in total cholesterol and 
this effect lasted until the 3-years follow-up. No differences in triglycerides and 
HDL-C were found. Stenvinkel et al. observed in their peritoneal dialysis group 
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an increase in total cholesterol and also HDL-C and a nearly signifi cant higher 
LDL-C after 12 months of dialysis (2). In our peritoneal dialysis population we 
found no signifi cant effects on the lipid profi le of the start of peritoneal dialy-
sis. 
An imbalance between pro- and anti-oxidant capacity results in an increased 
oxidative stress (4;15;16). In ESRD the loss of anti-oxidant defense is caused, 
amongst others, by reduced levels of vitamin C, lower intra-cellular levels of 
vitamin E, reduced selenium concentrations and defi ciency in the glutathione 
scavenging system. The pro-oxidative burden will be increased as a result of 
the uremic toxicity, malnutrition, chronic infl ammation and disturbed lipid pro-
fi le. Stenvinkel et al. observed after 12 months of dialysis therapy (both hemo-
dialysis and peritoneal dialysis) a higher plasmalogen concentration possibly 
indicating a reduction in oxidative burden during dialysis (2). This suggests that 
reducing the uremic burden could improve the balance between pro- and anti-
oxidant effects. 
However, repetitive blood membrane contact in hemodialysis induces comple-
ment activation, leukocyte activation and other pro-infl ammatory changes with 
increased production of cytokines and oxidants (17). Hemodialysis may further 
disturb the balance between oxidants and anti-oxidants due to diffusion (18). 
Data on oxidative stress in patients with ESRD and on dialysis are somewhat 
confl icting: some authors indeed found higher levels of oxidative stress (2;19-
22) whereas others did not (23-25). An important pitfall in interpreting and com-
paring studies on oxidative stress, is the difference in markers used to measure 
the amount of oxidative stress (26). Furthermore differences in population char-
acteristics (e.g. the number of diabetic patients, the age of the patients, the 
medication used etc.) may infl uence the outcome. In the present study, we 
found no net differences in the amount of oxidative stress regarding the lag time 
and lipid peroxides, following six months of treatment with hemodialysis or 
peritoneal dialysis. The fact that we did not fi nd a higher amount of oxidative 
stress in both groups can possibly be explained by clearance of uremic toxins 
that are associated with oxidative stress, chronic infl ammation and atheroscle-
rosis (27). Furthermore, anemia is associated with increased oxidative stress in 
ESRD (28). The raise in hemoglobin we found during the fi rst six months of 
treatment could have contributed to a lower pro-oxidative state. Although the 
possibility of increased availability of anti-oxidants through a higher level of 
erythrocytes is suggested (29), the mechanism is not fully understood: hypoxia 
and an altered catecholamine metabolism might play a role (30). Moreover, dur-
ing the fi rst six months of treatment, all patients started treatment with vitamin 
C (1 dd 50mg) to compensate the loss of this water-soluble vitamin due to the 
dialysis treatment. This could possibly diminish the amount of oxidative stress 
(31). 
From our study we conclude that the level of oxidative stress in ESRD does not 
change after the start of dialysis. The treatment with anti-oxidants remains a 
matter of debate. In a large trial, anti-oxidant vitamins did have no effects on 
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5-year mortality nor on various secondary endpoints (32). A meta-analysis of 
randomized trials (33) also revealed no benefi cial effects of vitamin E on mortal-
ity or cardiovascular events. On the other hand, it has been suggested that 
vitamin E and acetylcysteine may improve the anti-oxidative capacity and 
therefore could have benefi cial effects on the outcome in populations with 
ESRD (34;35). The use of vitamin E coated membranes in hemodialysis is 
widely under investigation and can possibly further contribute to a reduction of 
the oxidative burden during hemodialysis (36;37).
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Abstract 
Background 
Cardiovascular disease as a result of accelerated atherogenesis is common in 
patients with end-stage renal disease (ESRD). Dyslipidemia may be a major 
contributor in this process and can be infl uenced by lipid-lowering drugs (stat-
ins). Moreover, statins may exhibit additional inhibitory effects on the athero-
genesis, such as a modulation of the immune system as triggered by oxida-
tively modifi ed LDL and a reduction of the infl ammatory marker C-reactive 
protein (CRP).
Methods
We evaluated in a single-blind randomized trial of 28 ESRD patients on hemo-
dialysis, the dose-depending effects of both atorvastatin and simvastatin on 
lipids, lipoproteins, LDL particle heterogeneity, high sensitive-CRP (hs-CRP), 
and markers of in vivo LDL-oxidation.
Results
Both statin therapies signifi cantly lowered total plasma cholesterol and LDL-
cholesterol concentrations to the same extent, whereas reduction in the con-
centrations of triglyceride-rich particles was less pronounced. Furthermore, 
statin therapy reduced LDL-cholesterol in all LDL subfractions, without altering 
the overall LDL particle density. After both statins plasma, hs-CRP concentra-
tions were not signifi cantly reduced; parameters of in vivo LDL-oxidation 
(plasma ox-LDL concentration and the oxidation level of isolated LDL), were 
signifi cantly decreased. Auto-antibodies against ox-LDL, however, did not 
change during this trial period.
Conclusions
These results show that atorvastatin and simvastatin exhibit comparable 
favourable effects on lipid profi les in ESRD. Moreover, the reduction of in vivo 
oxidatively modifi ed LDL as shown in this ESRD population, may indicate that 
these statins exhibit favourable effects on oxidative stress in vivo.
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Introduction
Cardiovascular disease in end-stage renal disease (ESRD) is responsible for the 
majority of morbidity and mortality in patients on hemodialysis. A major contrib-
uting factor in the accelerated atherogenesis in these patients may be the fre-
quently observed dyslipidemia, manifest in both quantitative and qualitative 
alterations in lipid- and lipoprotein-levels. Especially elevated levels of triglyc-
erides, decreased levels of high-density lipoprotein (HDL) cholesterol and pres-
ence of small-dense low-density lipoprotein (LDL) particles, more prone to 
oxidative modifi cation, are characteristic for ESRD (1-5). 
Because of the poor life expectancy in ESRD patients, the initiation of lipid-
lowering therapy is increasingly considered for this population. However, the 
fear for side effects of drugs in general probably limits the large-scale use of 
lipid-lowering drugs in ESRD patients so far. Furthermore, fi brates, the most 
potent class of drugs for the treatment of hypertriglyceridemia, are not recom-
mended in ESRD patients or only advized in low dosages, because of a pre-
dominantly renal clearance. In increasingly higher dosages, fi brates have been 
associated with the development of rhabdomyolysis. In contrast, the most 
effective cholesterol lowering HMG-CoA reductase inhibitors (statins) have less 
effect on triglyceride concentration. However, in non-renal disease patients, 
atorvastatin has been reported to be more effective in lowering triglyceride 
levels than other statins, at least in the lower dosage level (6). Recently, the 
safety of treatment with simvastatin in patients undergoing chronic renal dialy-
sis was demonstrated (7).
Measurement of C-reactive protein (CRP) may provide a useful method of 
assessing the risk of cardiovascular disease, particularly in persons with normal 
or moderately elevated lipid levels, as it refl ects a process of chronic infl amma-
tion (8). Several studies suggest that statins have a number of in vivo effects, in 
addition to their lipid-lowering capacity, including the reduction of different 
infl ammatory mediators, such as CRP (8). Furthermore, growing evidence sug-
gests that the immune system plays an important role in the development of 
atherosclerosis and that oxidized low-density lipoprotein (ox-LDL) is one of the 
key mediators in this process (9). Because ox-LDL induces atherosclerosis by 
stimulating monocyte infi ltration and smooth muscle cell migration and prolif-
eration, measuring the amount of circulating ox-LDL may be used to predict 
cardiovascular risk (10).
In the present study we evaluated the dose-depending effects of both atorvas-
tatin and simvastatin on lipids, lipoproteins and LDL heterogeneity to investi-
gate possible differences in lipid-lowering, e.g. triglyceride-lowering, capacity. 
Furthermore, we determined to what extent both statins were able to reduce 
the concentration of CRP, circulating ox-LDL and antibodies to ox-LDL, in 
patients with ESRD on hemodialysis.
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Subjects and methods
Study population
For this study, 28 patients, established on hemodialysis for at least 6 months in 
stable clinical condition, were recruited from the nephrology department of the 
Rijnstate Hospital in Arnhem, the Netherlands. None of the included patients 
was known to have diabetes mellitus, hypothyroidism or familial dyslipidemia. 
Patients using beta-blockers were also excluded, because of possible effects 
on lipid metabolism. Approval for this study was obtained from the local ethical 
committee and each patient gave written informed consent before entering the 
study.
Study design
Patients received either atorvastatin or simvastatin. The groups were treated for 
18 weeks with increasing doses of 10 mg/day, 20 mg/day and 40 mg/day each 
for 6 weeks. At week 0, 6, 12 and 18 blood samples were taken. At each time 
point total plasma cholesterol, total plasma triglycerides and HDL-cholesterol 
were determined and LDL-cholesterol was calculated using the Friedewald 
formula. At week 0 and 18, an extended lipoprotein analysis, including the 
determination of VLDL-cholesterol and VLDL-triglycerides was performed and 
the LDL subfraction profi le was determined. Furthermore, concentrations of 
high sensitive CRP (hs-CRP), in vivo ox-LDL and IgG and IgM antibodies to in 
vivo ox-LDL were determined at week 0, 12 and 18.
Laboratory measurements
Blood samples were obtained after an overnight fast at the start of the dialysis 
sessions before the addition of heparin and col lected into vacutainers contain-
ing 1 mg/ml of EDTA. Plasma was isola ted immediately and saccharose (fi nal 
concentration 0.6 %) was added to prevent denaturation of lipoproteins during 
freezing. Samples were stored at -80 oC. 
Very low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL) 
were isolated together by ultracentrifugation at density 1.019 g/ml for 16 hours 
at 40,000 rpm in a fi xed angle rotor (TFT 45.6 rotor, Kontron, Zürich), in a Beck-
man L7-55 ultracentrifuge (Beckman, Palo Alto, USA) (11). HDL was isolated 
from whole plasma by the polyethylene glycol method (12). Cholesterol and 
triglycerides were determined by enzymatic methods (Boehringer-Mannheim, 
Mannheim, Germany (cat. no. 237574) and Sera Pak, Miles, Tournay, Belgium 
(cat. no. 6669), respectively) with an automated analyzer. Cholesterol and trig-
lycerides were measured in total plasma and in the remaining plasma after 
removal of isolated VLDL+IDL. Subsequently, VLDL+IDL-cholesterol and trig-
lyceride were calculated by substraction.
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LDL subfraction analysis before and after treatment was performed by density 
gradient ultracentrifugation (2). The samples of each patient were analyzed in 
the same run. After ultracentrifugation up to 4 LDL subfractions could be dis-
tinguished in the following density ranges: LDL1 (1.030-1.033 g/ml), LDL2 
(1,033-1.040 g/ml), LDL3 (1.040-1.045 g/ml) and LDL4 (1.045-1.054 g/ml). 
The ultracentrifugation tubes, containing the LDL subfractions stained with 
Coomassie Brilliant Blue R, were placed in a specially designed rack and pho-
tographed. Accurate documentation of the different LDL subfraction patterns 
was obtained by determining the cholesterol level of the visible bands repre-
senting a LDL subfraction, as described elsewhere (13). The relative peak 
heights (h1 to h5) of the LDL subfractions (LDL1 to LDL5) were used to calcu-
late parameter K as a continuous variable, to describe each individual LDL-
subfraction pattern (13). A negative value (-1<K<0) refl ects a dense subfraction 
profi le, an intermediate subfraction profi le is described by K=0, and a complete 
buoyant profi le delivers a positive K value (0<K<1) (13).
Hs-CRP was measured by a commercially available ELISA (Kordia, Leiden, The 
Netherlands) according to the instructions of the manufacturer (14). 
Ox-LDL in plasma and in isolated LDL was measured by a sandwich ELISA 
using the monoclonal antibody 4E6 (generously supplied by Dr. Holvoet, Cath-
olic University of Leuven, Belgium) as the capture antibody and anti-human 
apoB-100 polyclonal antibody for detection. Monoclonal antibody 4E6 is direct-
ed against a conformational epitope in the apoB-100 moiety of LDL that is 
generated as a consequence of aldehyde substitution of lysine residues of 
apoB-100 (10). Thus, the antibody is specifi c for oxidatively modifi ed LDL (15). 
Ox-LDL in LDL samples was expressed as percentage ox-LDL (=LDL-oxidation 
level) by relating the amount of ox-LDL detected to the amount of LDL added 
to the well. Plasma levels of ox-LDL were both deduced from LDL-oxidation 
levels by multiplication with plasma LDL-cholesterol levels, as well as deter-
mined directly by assaying plasma samples at 1000-fold dilution in the ELISA. 
We observed a good correlation ( r=0.72, p<0.0001, n=52) between measure-
ments of ox-LDL in isolated LDL and in plasma, suggesting that both assays 
specifi cally detect ox-LDL.
Auto-antibodies to ox-LDL were measured as described previously (16).
Statistical analysis
Results are expressed as mean ± standard deviation. Statistical analysis of 
alterations within one group of treatment, was performed with Wilcoxon’s 
Signed Rank test. Differences in percentage between the 2 groups of treatment 
were analyzed with Wilcoxon’s Rank Sum test. The differences before and after 
therapy for the whole group of participants were analyzed by the Wilcoxon’s 
Signed Rank test. A 2-tailed probability value <0.05 was considered signifi cant. 
The statistical analyzes were performed with procedures available in the SPSS 
(Statistical Package for the Social Sciences) software package version 9.0. 
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Results
Twenty-eight patients described in this study met the inclusion criteria. Fifteen 
patients received simvastatin (13 men and 2 women); they all fi nished the pro-
tocol. Of the 13 patients who received atorvastatin (8 men and 5 women), 2 
women ended therapy because of nausea at the initial dose of 10 mg/day. Their 
baseline results were excluded from further analysis. No other side effects were 
reported during statin therapy. Baseline characteristics of the study population 
are shown in table 1. Age, BMI and smoking behaviour were not signifi cantly 
different between the two treatment groups. 
Tabel 1. Characteristcs of participants
Atorvastatin Simvastatin All 
Number 13 15 28
Male : Female 8 : 5 13 : 2 21 : 7
Age (years)a 64.1 ± 16.2 65.8 ± 12.7 65.0 ± 14.2
Body mass index (kg/m2)a 24.3 ± 4.5 24.3 ± 3.8 24.3 ± 4.1
Smoking (% of total) 4 (31) 6 (40) 10 (36)
Overt cardiovascular disease (% of total)b 10 (77) 6 (40) 16 (57)
a presented as means ± standard deviation
b defi ned by the patiënt’s doctor as prior myocardial infarction, cerebrovascular accident or 
manifest angina pectoris and/or peripheral vascular disease
Table 2 shows the effects of 18 weeks treatment on lipid profi le in the partici-
pants on simvastatin, those on atorvastatin or all participants together. Total 
cholesterol and LDL-cholesterol concentrations signifi cantly decreased follow-
ing statin therapy. Triglycerides, VLDL-triglycerides, VLDL-cholesterol and 
HDL-cholesterol did not change signifi cantly. For all these parameters, no sig-
nifi cant differences between the two statin groups were observed. Initially, an 
IDL subfraction profi le was present in all patients (mean K≈0), with a distribution 
of the LDL subfractions in both statin groups comparable with normal controls 
(data controls not shown). Statin treatment reduced cholesterol in all LDL sub-
fractions (signifi cantly in the LDL subfractions 1 to 3), but did not change the 
LDL subfraction profi le (fi gure1). 
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Figure 1   Effect of treatment with either simvastatin or atorvastatin on the 
 cholesterol content in mmol/l of four LDL subfractions (LDL1-LDL4) 
* p<0.05
Due to technical problems only suffi cient material of all patients, for the exten-
sive determinations of LDL-oxidation, was left from baseline and week 12. 
Therefore, results presented here refl ect the effects after 12 weeks of treatment. 
These results were, however, comparable with those obtained at week 18. 
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Tabel 2.  Levels of lipids, lipoproteins and K-value at baseline and after treatment with increasing 
doses of either atorvastatin or simvastatin
Parametera Drug Baseline 10 mg 20 mg 40 mg Change (%)b
TC Ac 4.80 ± 1.23 3.63 ± 0.76* 3.42 ± 0.71* 3.55 ± 0.89* -25.1 ± 12.5*
Sd 4.48 ± 1.05 3.44 ± 0.68* 3.36 ± 0.44* 3.32 ± 0.63* -23.9 ± 15.6*
Alle 4.61 ± 1.12 3.52 ± 0.71* 3.39 ± 0.56* 3.42 ± 0.75* -24.4 ± 14.5*
TG Ac 1.81 ± 0.77 1.74 ± 0.84 1.53 ± 0.58 1.50 ± 0.55 -12.7 ± 26.1
Sd 1.63 ± 0.99 1.28 ± 0.51 1.56 ± 1.12 1.52 ± 0.94 -5.0 ± 23.7
Alle 1.71 ± 0.89 1.47 ± 0.69 1.55 ± 0.91 1.51 ± 0.78 -8.4 ± 24.5
VLDL
+IDL-C
Ac 0.91 ± 0.45 n.d.f n.d.f 0.70 ± 0.36 -17.5 ± 36.3
Sd 0.80 ± 0.55 n.d.f n.d.f 0.64 ± 0.44 -14.3 ± 40.9
Alle 0.84 ± 0.50 n.d.f n.d.f 0.66 ± 0.40 -15.7 ± 38.2
VLDL
+IDL-TG
Ac 1.23 ± 0.75 n.d.f n.d.f 1.00 ± 0.51 -10.6 ± 34.6
Sd 1.12 ± 0.97 n.d.f n.d.f 1.05 ± 0.96 -4.7 ± 31.3
Alle 1.17 ± 0.87 n.d.f n.d.f 1.02 ± 0.78 -7.3 ± 32.2
HDL-C Ac 0.96 ± 0.36 0.97 ± 0.37 0.98 ± 0.35 1.00 ± 0.35 +6.5 ± 13.8
Sd 0.93 ± 0.28 0.98 ± 0.25 0.97 ± 0.24 0.90 ± 0.25 -0.2 ± 11.4 
Alle 0.94 ± 0.31 0.97 ± 0.30 0.98 ± 0.29 0.98 ± 0.31 +2.9 ± 12.6 
LDL-C Ac 2.94 ± 0.97 1.93 ± 0.66* 1.82 ± 0.58* 1.85 ± 0.67* -35.5 ± 16.5*
Sd 2.73 ± 0.80 1.93 ± 0.59* 1.74 ± 0.47* 1.75 ± 0.48* -32.4 ± 21.5*
Alle 2.82 ± 0.87 1.93 ± 0.60* 1.77 ± 0.51* 1.79 ± 0.55* -33.7 ± 19.2* 
K-value Ac -0.04 ± 0.24 n.d.f n.d.f -0.04 ± 0.22 +4.4 ± 10.4
Sd 0.01 ± 0.25 n.d.f n.d.f  0.03 ± 0.22 +5.7 ± 18.8
Alle -0.01 ± 0.25 n.d.f n.d.f  0.00 ± 0.22 +5.2 ± 15.8
a All values presented in mmol/l as mean ± standard deviation
b Percentual change ± standard deviation after intervention as compared with baseline 
c atorvastatin
d simvastatin
e All: all patients together 
f  n.d.: not determined
* p<0.01 as compared with baseline
Abbreviations: 
TC: total cholesterol; TG: triglycerides; VLDL-C: very low-density lipoprotein-cholesterol; VLDL-TG: 
very low-density lipoprotein-triglycerides; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-
density lipoprotein-cholesterol
The effect of statin treatment on hs-CRP, ox-LDL and auto-antibodies to ox-
LDL are presented in table 3. At baseline hs-CRP was increased in both groups 
(normal level <2 mg/l). The observed modest reduction in hs-CRP following 
statin therapy was not signifi cant. IgG and IgM auto-antibodies to ox-LDL did 
not change during the trial period. Following statin treatment, LDL-oxidation 
levels decreased signifi cantly, both to an equal extent. The absolute concentra-
tion of circulating ox-LDL, obtained by multiplication of LDL-oxidation level by 
the plasma LDL-cholesterol concentration, also decreased signifi cantly in both 
groups. Similar results were obtained when ox-LDL was determined directly in 
plasma (table 3).
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Tabel 3.  Plasma concentration of high sensitive C-reactive protein (hs-CRP), IgG and IgM antibod-
ies to ox-LDL and in vivo ox-LDL before and after statin therapy
Parametera Drug Baseline 20 mg Change (%)b
High sensitive CRP (mg/l) Ac 18.7 ± 25.6
(11.1; 1.7 to 83.1)f
16.3 ± 23.2
(9.0; 2.2 to 72.1)f
-16.1 ± 24.5
Sd 21.0 ± 20.0
(14.8; 3.2 to 57.9)f
18.7 ± 19.8
(6.0; 1.4 to 48.7)f
-13.7 ± 51.5
Alle 20.0 ± 22.1
(13.4; 1.7 to 83.1)f
17.7 ± 20.7
(6.4; 1.4 to 72.1)f
-14.7 ± 41.4
Ox-LDL IgG (E450nm) Ac 0.10 ± 0.03 0.10 ± 0.03 +3.1 ± 17.4
Sd 0.13 ± 0.08 0.15 ± 0.09 +6.7 ± 19.5
Alle 0.12 ± 0.07 0.13 ± 0.08 +5.0 ± 18.1
Ox-LDL IgM (E450nm) Ac 0.38 ± 0.31 0.40 ± 0.34 +11.4 ± 15.4
Sd 0.34 ± 0.21 0.35 ± 0.21 +2.3 ± 22.5
Alle 0.36 ± 0.25 0.38 ± 0.28 +6.4 ± 19.7
Ox-LDL (% of LDL)
(=LDL-oxidation level)
Ac
Sd
2.4 ± 0.8
2.3 ± 1.1
1.2 ± 0.3**
1.5 ± 0.6*
-48.2 ± 15.8**
-26.1 ± 33.0* 
Alle 2.4 ± 1.0 1.4 ± 0.52** -36.1 ± 28.4**
Ox-LDL (µmmol/l)
(calculated from 
LDL-oxidation level)
Ac
Sd
69 ± 33
70 ± 51
20 ± 7**
29 ± 18**
-65.5 ± 18.5**
-48.5 ± 29.3**
Alle 69 ± 43 25 ± 14** -56.2 ± 25.9**
Total ox-LDL(µmg/ml 
plasma)
(determined in plasma 
directly)
Ac
Sd
83.2 ± 20.0
91.0 ± 53.5
46.8 ± 17.1**
57.2 ± 18.6**
-43.2 ± 18.5**
-26.1 ± 27.4**
Alle 87.5 ± 41.1 52.3 ± 18.3** -33.8 ± 23.1**
Due to technical problems only suffi cient material for the extensive determinations of LDL-oxida-
tion, was left from baseline and week 12 (after 20 mg of statin/day).
a All values are presented in mmol/l as mean ± standard deviation
b Percentual change ± standard deviation after intervention as compared with baseline
c atorvastatin
d simvastatin
e All: all patients together 
f median with range
* p<0.05 as compared with baseline 
** p<0,01 as compared with baseline 
Discussion
Since life expectancy in ESRD patients on hemodialysis tends to increase 
due to all kind of preventive measures and improving dialysis techniques, it 
becomes increasingly important to infl uence benefi cially with established risk 
factors for cardiovascular disease as well. This study assessed both the lipid-
lowering properties of statins, as well as the effect of these class of drugs on 
CRP level, a marker of blood vessel wall infl ammation, and the formation of 
ox-LDL, a pivotal parameter in atherogenesis. 
At baseline the total cholesterol level of our study population with ESRD was in 
the normal range. However, an elevated fasting triglyceride level, a reduced 
HDL-cholesterol level and an IDL subfraction profi le were observed. We found 
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that both atorvastatin and simvastatin signifi cantly reduced lipid and lipoprotein 
concentrations to an equal extent and that there were, even in the lowest dose, 
no signifi cant differences between these statins concerning their lowering 
effect on triglyceride-containing lipoproteins. Both the absolute and percentual 
reductions corresponded well with the recently reported results after simvasta-
tin treatment in ESRD by Saltissi et al. (7). Although the current study was not 
meant to evaluate adverse effects of statins, both drugs were well tolerated in 
these ESRD patients.
Recent studies suggest that statin therapy may have a number of benefi cial 
effects, which may still be caused by infl uencing the mevalonate pathway; 
these including improvement of endothelial function and reduction of several 
infl ammatory mediators (8). In the present study we observed elevated hs-CRP 
levels at baseline, refl ecting an infl ammatory status in these ESRD patients. We 
could observe a slight decrease in the hs-CRP concentration after statin thera-
py. Although less pronounced here, this fi nding corresponds with the recent 
report of Chang et al., who showed a signifi cant reduction of hs-CRP after 8 
weeks of simvastatin 20 mg/day in hemodialysis (5). Since interfering diseases 
were not observed and no alterations in the dialysis technique took place, this 
CRP reduction suggests an anti-infl ammatory effect of statin therapy in hemo-
dialysis patients. Considering that infl ammation is a part of the atherogenesis 
process, statins may therefore have a benefi cial effect on cardiovascular dis-
ease in hemodialysis (8). The fact that our results on hs-CRP were not signifi -
cant may be due to the small number of patients in the study and the use of 
another dialysis technique, which may infl uence hs-CRP levels as well.
Ox-LDL and auto-antibodies to ox-LDL play a pivotal role in the development 
of atherosclerosis (17,18). Atherogenic ox-LDL increases progressively during 
the development of renal failure, suggesting that the oxidation of LDL may be 
associated with endothelial injury and atherogenesis in these patients (9). In our 
study the concentration of circulating ox-LDL as well as the level of LDL-oxida-
tion were signifi cantly reduced. No changes in the concentration of autoanti-
bodies against ox-LDL (IgM and IgG) were observed. However, detectable 
alterations in the immunologic response against diminishing ox-LDL particles 
may take place only after a longer period of time.
As previously reported, the more dense LDL-3 and LDL-4 subfractions are more 
susceptible to in vitro oxidative modifi cation than the buoyant LDL-1 and LDL-
2 subfractions (2). Accordingly, a correlation between overall LDL density and 
in vitro oxidizability is frequently observed. In our study population, initially an 
overall IDL subfraction profi le, expressed by the K-value ≈ 0 was present in all 
participants. Both statins signifi cantly reduced cholesterol in all LDL subfrac-
tions. Therefore, no shift towards a more buoyant LDL, in general less prone to 
oxidative modifi cation, was observed. We concluded that the reduction in ox-
LDL after statin therapy could be explained by the reduction of LDL-3 and LDL-
4 particles. However, other potential mechanisms were recently reported (19).
It is concluded that even with relatively normal lipid and lipoprotein profi les, as 
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observed in these ESRD patients, statin therapy could be considered to prevent 
accelerated atherogenesis. Moreover, factors, such as the infl ammatory status 
and LDL-oxidation may be indirectly infl uenced by the use of statins. Long-term 
intervention studies are underway to show the impact on cardiovascular mor-
bidity and mortality in this group of patients.
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Abstract
Objectives
The objectives of this study were to examine the effects of treatment with ator-
vastatin, alpha-tocopherol and the combination of both, on lipoproteins and 
oxidative stress in dialysis patients.
Methods
This double blind randomized placebo controlled trial was performed at the 
dialysis department of a non-university hospital.
44 clinically stable, non-diabetic patients on dialysis therapy (23 on hemo- and 
21 on peritoneal dialysis) without manifest cardiovascular disease were included 
in this study. They were randomized for treatment during a period of 12 weeks 
with 40 mg atorvastatin + placebo alpha-tocopherol (group 1) once daily, 800 IU 
alpha-tocopherol + placebo atorvastatin once daily (group 2), 40 mg atorvastatin 
+ 800 IU alpha-tocopherol once daily (group 3), or placebo atorvastatin + 
placebo alpha-tocopherol once daily (group 4). Assessment of lipid profi le and 
oxidative stress was performed at the start of the study and after 12 weeks of 
treatment. 
Results
Treatment with atorvastatin reduced total cholesterol, triglycerides, low-density 
lipoprotein cholesterol, apolipoprotein B and levels of oxidized LDL with 
30-43%. It had no infl uence on LDL oxidizability. Additional supplementation 
with alpha-tocopherol had no effect on lipid profi le and oxidized LDL levels but 
decreased in vitro LDL oxidizability. No side effects were observed. 
Conclusions
Treatment with atorvastatin is effective in lowering plasma total cholesterol, 
triglycerides, low-density lipoprotein, apolipoprotein B and oxidized LDL in a 
population of stable dialysis patients and might therefore be an effective tool in 
improving the poor cardiovascular outcome in these patients. Supplementation 
of alpha-tocopherol to atorvastatin had benefi cial effects on in vitro LDL oxidiz-
ability and might therefore be of additional value. Further research on the clini-
cal effects of treatment with atorvastatin in combination with alpha-tocopherol 
is necessary.
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Introduction
Cardiovascular disease is the most important cause of morbidity and mortality in 
patients with end-stage renal disease (ESRD) treated with maintenance dialysis. 
Patients with ESRD have a highly atherogenic lipid profi le and increased levels of 
oxidized LDL (ox-LDL) which are associated with atherosclerosis and cardiovas-
cular disease (1;2). Treatment of dyslipidemia in non-renal patients with statins 
has been shown to be effective in improving the lipid profi le, reducing cardiovas-
cular events and improving survival (3). In dialysis patients, treatment with statins 
also appeared to be save and effective in improving lipid abnormalities (4). Fur-
thermore, statins were shown to have benefi cial effects on the oxidizability of LDL 
and circulating ox-LDL levels (5). An observational study in a cohort of dialysis 
patients showed that the use of statins was associated with reduced mortality (6). 
However, data on clinical endpoints from prospective, randomized controlled tri-
als of statins in patients with ESRD are lacking. 
Since ESRD and dialysis therapy are associated with enhanced oxidative stress 
and this is thought to play an important role in atherogenesis, patients with 
ESRD and on dialysis therapy might benefi t from anti-oxidant therapy. Supple-
mentation with vitamin E in both renal and non-renal populations indeed has 
benefi cial effects on oxidative stress and (surrogate) markers of atherosclerotic 
disease but the results on clinical endpoints in general have been disappoint-
ing. A recent meta-analysis on this subject concluded that there is no indication 
for routine use of anti-oxidants in order to improve cardiovascular outcome (7). 
However, most studies are performed in patients without renal disease and the 
only prospective study on secondary prevention with anti-oxidants in dialysis 
patients, reported a reduction in composite cardiovascular endpoints (8). In 
order to try to understand the effects of intervention with statins and vitamin E, 
we performed a prospective, double blind, randomized placebo-controlled trial 
of treatment with atorvastatin and alpha-tocopherol in dialysis patients and 
studied the effects on lipoproteins and oxidative stress.
Materials and methods
Study population and medication
We studied 44 clinically stable non-diabetic patients without manifest cardio-
vascular disease on dialysis therapy (23 on hemodialysis and 21 on peritoneal 
dialysis). None of the patients used lipid-lowering drugs. All patients were 
treated in the dialysis unit of the Isala Clinics, location Weezenlanden, Zwolle, 
the Netherlands. 
Patients were randomized for treatment with once daily 40 mg atorvastatin + 
placebo alpha-tocopherol (group 1), once daily 800 IU alpha-tocopherol + pla-
cebo atorvastatin (group 2), once daily 40 mg atorvastatin + once daily 800 IU 
alpha-tocopherol (group 3), or placebo atorvastatin + placebo alpha-tocopherol 
(group 4). 
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All patients gave their informed consent. The hospital’s Medical Ethical Com-
mittee approved the study.
Pfi zer® (Capelle aan den IJssel, The Netherlands) supplied the atorvastatin and 
placebo tablets. The hospital’s pharmaceutical department manufactured cap-
sules with alpha-tocopherol and placebo. 
Laboratory measurements
Blood samples were taken before the start of the study and after 12 weeks of 
treatment. Patients were instructed to take a light, low fat containing meal, con-
sisting of tea and a jelly sandwich, on the day of the blood sample collection. In 
the hemodialysis-patients, blood samples were taken just before a dialysis ses-
sion. Venous blood was collected in EDTA Vacutainer® tubes (Becton Dickin-
son, Heidelberg, Germany). The blood samples were immediately placed on ice 
and plasma was obtained by centrifugation (3000 rpm) at 4 ºC within 30 minutes. 
Plasma, supplemented with saccharose (0.6% w/v) as a cryoprotectant, was 
frozen on liquid nitrogen and stored at –80 ºC until analysis. 
Plasma total cholesterol (Chol), high-density lipoprotein cholesterol (HDL), trig-
lycerides (TG), creatinin and blood urea nitrogen (BUN), were measured on a 
Hitachi 917 analyzer, using Roche reagents (Roche, Mannheim, Germany). 
Low-density lipoprotein cholesterol (LDL) was calculated using the Friedewald 
formula. Hemoglobin (Hb) was measured on a Sysmex XE-2100 (Toa Medical 
Instruments, Kobe, Japan). 
Apolipoprotein B was analyzed on the Hitachi 912 chemistry analyzer using 
Roche reagents (Roche, Almere, The Netherlands).
After thawing of the plasma sample, LDL was isolated by density-gradient ultra-
centrifugation (40.000 rpm in a SW 40 rotor for 18 h at 4 0C, Beckman, Palo Alto, 
CA, USA). The protein content of the LDL fraction was measured and LDL-oxi-
dation assays were performed as described by Kleinveld et al. (9). Briefl y, the 
oxidation of LDL (60 µg apolipoprotein/ml) was initiated by the addition of CuSO4 
(fi nal concentration of 18 µM) at 37 0C. The kinetics of the oxidation of LDL was 
determined by monitoring the change of the 234 nm diene absorption in a water-
thermostated UV spectrophotometer (Lambda 12, Perkin Elmer, GmBH, Ger-
many), equipped with an 8-position automatic row-sampler changer. Each LDL 
preparation was oxidized twice, in two separate oxidation runs on the same day. 
Every oxidation run was controlled by analyzing one reference LDL, freshly pre-
pared from pooled plasma stored with 6 g/l saccharose at –80 0C. 
Plasma ox-LDL was measured using the Mercodia ox-LDL kit (Mercodia®, 
Uppsala, Sweden). This immunoassay is based on the direct sandwich tech-
nique and uses two monoclonal antibodies that are directed against separate 
antigenic determinants on the oxidized apolipoprotein B molecule. The intra- 
and interassay coeffi cient of variation amount to 6% and 7%, respectively.
Concentrations of vitamin E in serum and LDL were analyzed by reversed-
phase high-performance liquid chromatography. 
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An indication of normal values of lag time (10), ox-LDL (Mercodia, Sweden), ratio 
ox-LDL/apoB, serum vitamin and vitamin E in LDL (11) is listed in table 1.
Table 1.  Normal values of lag time, ox-LDL, ratio ox-LDL/apoB, serum vitamin E and vitamin E 
in LDL.
Parameter Value
lag time (minutes) 70.4 ± 11.1
ox-LDL (IU/l) 61 
ratio ox-LDL/apoB (IU/mg) >0.05 
serum vitamin E (mg/l plasma) 26.3 ± 3.6 
vitamin E in LDL (mg/g LDL protein) 14.1 ± 1.2
Values are expressed as mean ± standard deviation
Statistical analysis
Statistical analysis was performed using SPSS 11.0 for Windows. Values are 
expressed as mean ± standard deviation. 
The Wilcoxon signed rank test was used to compare differences in continuous 
variables within groups after intervention. Oneway ANOVA with Bonferroni cor-
rection was performed to compare baseline differences between groups. P-
values equal to or less than 0.05 were considered statistically signifi cant. Pear-
son correlation test was used to calculate correlations between two variables.
Results
Demographic characteristics of the study population are presented in table 2. 
There were no signifi cant differences between the four groups, although groups 
1 and 4 have been subjected longer to dialysis therapy than groups 2 and 3. 
Patients experienced no side effects of the medication during the study period. 
Separate analysis of hemo- and peritoneal dialysis groups showed comparable 
results and therefore the results of the interventions are described together.
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Table 2.  Baseline demographic and treatment characteristics of the dialysis patients by groups
Randomizationa Group 1 (n=13) Group 2 (n=10) Group 3 (n=11) Group 4 (n=10)
male: female 9:4 8:2 5:6 8:2
age (years) 46 ± 15 47 ± 16 51 ± 20 51 ± 18
duration of dialysis (months) 118 ± 107 55 ± 31 56 ± 30 118 ± 79
RR systolic (mmHg) 142 ± 30 153 ± 26 147 ± 21 156 ± 33
RR diastolic (mmHg) 87±16 93 ± 18 89 ± 13 91 ± 15
body mass index (kg/m2) 24.6 ± 4.6 23.5 ± 2.8 24.5 ± 3.1 26.0 ± 5.4
Hb (mmol/l) 7.0 ± 0.8 7.2 ± 0.6 7.4 ± 1.2 7.1 ± 1.0
creatinin (µmol/l) 1077 ± 350 916 ± 87 953 ± 261 1071 ± 183
blood urea nitrogen (mmol/l) 23.4 ± 5.5 27.4 ± 4.5 24.9 ± 5.3 26.0 ± 3.8
antihypertensive drugs ≥ 1 3 (23%) 4 (40%) 3 (27%) 7 (70%)
phosphatebinding drugs ≥ 1 13 (100%) 10 (100%) 11 (100%) 10 (100%)
Dialysis treatment
weekly hemodialysis duration 
(hours) 
daily peritoneal dialysis 
treatment (liters) 
11.8 ± 1.1 
10.5 ± 2.6
12.5 ± 1.6
8.1 ± 2.7
10.5 ± 1.0
9.2 ± 1.8
12.0 ± 2.4
10.6 ± 2.5
Values are expressed as mean ± standard deviation
No differences were found between the four groups regarding the described characteristics.
a Randomization:
Group 1 = atorvastatin + placebo
Group 2 = alpha-tocopherol + placebo 
Group 3 = atorvastatin + alpha-tocopherol 
Group 4 = placebo + placebo    
Baseline values of total cholesterol, triglycerides, HDL-cholesterol, LDL-choles-
terol and apolipoprotein B did not differ between the groups (tables 3a-d). 
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Table 3a.  Results of treatment with atorvastatin + placebo alpha-tocopherol (group 1, n = 13) 
in dialysis patients 
Baseline 12 weeks Change (%) p-value
cholesterol (mmol/l) 5.1 ± 1.1 3.3 ± 0.9 -34 0.003
TG (mmol/l) 3.8 ± 3.3 2.4 ± 1.9 -34 0.003
HDL-C (mmol/l) 0.97 ± 0.3 0.94 ± 0.3 -1.9 0.834
LDL-C (mmol/l) 2.6 ± 0.9 1.3 ± 0.8 -43 0.016
ApoB (g/l) 1.0 ± 0.2 0.7 ± 0.2 -30 0.003
lag time (minutes) 93 ± 21 94 ± 20 1.9 0.388
ox-LDL (U/l) 46 ± 13 33 ± 11 -29 0.001
ratio ox-LDL/apoB (U/g) 47 ± 12 48 ± 9.6 5.6 0.507
serum vitamin E (µmol/l) 36 ± 15 30 ± 13 -4.8 0.023
vitamin E in LDL (µmol/g LDL protein) 16 ± 4.2 15 ± 3.9 -5.5 0.117
Values are expressed as mean ± standard deviation
Table 3b.  Results of treatment with alpha-tocopherol + placebo atorvastatin (group 2, n = 10) 
in dialysis patients
Baseline 12 weeks Change (%) p-value
cholesterol (mmol/l) 4.8 ± 1.1 4.8 ± 1.0 1.9 0.798
TG (mmol/l) 2.5 ± 1.5 2.3 ± 1.4 -4.2 0.477
HDL-C (mmol/l) 0.95 ± 0.3 0.98 ± 0.3 4.8 0.635
LDL-C (mmol/l) 2.7 ± 0.9 2.8 ± 1.0 4.4 0.445
ApoB (g/l) 1.0 ± 0.3 1.1 ± 0.3 5.8 0.114
lag time (minutes) 86 ± 17 98 ± 17 13 0.051
ox-LDL (U/l) 41 ± 9.3 49 ± 14 17 0.015
ratio ox-LDL/apoB (U/g) 42 ± 8.2 44 ± 7.5 9.8 0.110
serum vitamin E (µmol/l) 27 ± 4.6 51 ± 18 88 0.008
vitamin E in LDL (µmol/g LDL protein) 15 ± 2.7 21 ± 6.2 42 0.012
Values are expressed as mean ± standard deviation
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Table 3c.  Results of treatment with atorvastatin + alpha-tocopherol (group 3, n = 11) in dialysis 
patients
Baseline 12 weeks Change (%) p-value
cholesterol (mmol/l) 4.9 ± 1.2 3.1 ± 0.8 -37 0.003
TG (mmol/l) 1.7 ± 1.0 1.4 ± 0.7 -9.9 0.047
HDL-C (mmol/l) 1.46 ± 0.2 1.10 ± 0.2 -3.7 0.169
LDL-C (mmol/l) 3.0 ± 0.9 1.4 ± 0.6 -55 0.003
apoB (g/l) 1.1 ± 0.2 0.7 ± 0.2 -35 0.004
lag time (minutes) 88 ± 9.1 104 ± 12 19 0.003
ox-LDL (U/l) 44.8 ± 8.4 32.8 ± 9.8 -28 0.004
ratio ox-LDL/apoB (U/g) 42.6 ± 4.6 47.7 ± 4.2 13 0.021
serum vitamin E (µmol/L) 28.1 ± 9.3 40.1 ± 1 46 0.004
vitamin E in LDL (µmol/g LDL protein) 14.3 ± 2.0 23.3 ± 5.3 64 0.01
Values are expressed as mean ± standard deviation
 
Table 3d.  Results of treatment with placebo atorvastatin + placebo alpha-tocopherol (group 4, 
n = 10) in dialysis patients
Baseline 12 weeks Change (%) p-value
cholesterol (mmol/l) 4.8 ± 1.1 4.9 ± 0.8 4.2 0.609
TG (mmol/l) 2.6 ± 1.7 2.3 ± 1.2 -1.3 0.445
HDL (mmol/l) 0.92 ± 0.3 0.92 ± 0.3 -0.8 0.878
LDL (mmol/l) 2.7 ± 0.8 3.0 ± 0.8 12 0.028
apoB (g/l) 1.0 ± 0.3 1.1 ± 0.3 8.9 0.126
lag time (minutes) 90 ± 13 89 ± 11 -0.7 0.683
ox-LDL (U/l) 42 ± 12 43 ± 10 3.7 0.646
ratio ox-LDL/apoB (U/g) 41 ± 7.8 39 ± 7.3 -4.4 0.241
serum vitamin E (µmol/l) 29 ± 11 31 ± 11 5.7 0.333
vitamin E in LDL (µmol/g LDL protein) 14 ± 2.7 15 ± 3.2 9.8 0.326
Values are expressed as mean ± standard deviation
Treatment with atorvastatin (group 1) reduced total cholesterol, triglycerides, 
LDL-cholesterol and apolipoprotein B with 30-43%. These values were not 
infl uenced by additional supplementation with alpha-tocopherol (group 3). Sup-
plementation with alpha-tocopherol alone had no effect on the lipid profi le 
(group 2). 
Baseline values of lag time, ox-LDL, serum vitamin E and vitamin E per mg LDL 
protein, did not differ between the groups (tables 2a-d). While serum vitamin E 
and vitamin E per mg LDL protein were comparable to values of normal 
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subjects (26.3 ± 3.6 mg/l plasma and 14.1 ± 1.2 mg/gLDL protein, respectively), 
lag time of dialysis patients surprisingly was longer than in normal subjects 
(70.4 ± 11.1 minutes). Ox-LDL was slightly lower in dialysis patients than in 
normal subjects (median 59 U/l, range 26-117, data supplied by Mercodia), 
which may be due to the relatively low LDL levels. Normal values for ox-LDL/
apoB ratio are not known.
Before intervention, a positive correlation was found between ox-LDL and vita-
min E in serum (correlation coeffi cient 0.542, p<0.01) and vitamin E in LDL 
(correlation coeffi cient 0.345, p<0.01) in the total group. A negative correlation 
between lag time and vitamin E in LDL (correlation coeffi cient –0.511, p<0.01) 
was found in this population. 
After treatment with alpha-tocopherol (groups 2 and 3) the concentrations of 
vitamin E in plasma and in LDL were increased. The degree of increase did not 
differ between both groups. 
In addition to its effects on lipid profi le, atorvastatin (group 1) reduced the 
plasma level of ox-LDL and the concentration of vitamin E, but had no effect on 
vitamin E in LDL, the LDL oxidizability and the ratio ox-LDL/apoB. Additional 
suppletion of alpha-tocopherol did not infl uence the effect of atorvastatin on 
ox-LDL but led to a reduction of LDL oxidizability (group 3). Furthermore, a 
small increase in ox-LDL/apoB ratio was found. Treatment with alpha-tocophe-
rol alone (group 2) also prolonged the lag time by 13% (p=0.051). The concen-
tration of ox-LDL in plasma was increased after supplementation with alpha-
tocopherol alone but the ox-LDL/apoB ratio did not change (group 2).
Discussion
In the present study, we investigated the effects of treatment with atorvastatin 
in combination with the anti-oxidant alpha-tocopherol on biochemical variables 
of lipid profi le and oxidative stress, in order to gain insight in mechanisms 
underlying the benefi cial effects of these treatments in earlier studies.
We observed marked decreases in the concentrations of total cholesterol, 
triglycerides, LDL-C, apoB and circulating ox-LDL particles and a minimal 
decrease in serum vitamin E after treatment with atorvastatin (40 mg daily) in 
stable dialysis patients. Intervention with alpha-tocopherol (800 IU daily) raised 
serum vitamin E and vitamin E in LDL, prolonged the lag time of LDL-oxidation 
but also was associated with increased levels of ox-LDL. Treatment with 
alpha-tocopherol in combination with atorvastatin showed a decrease of concen-
tration of lipids and ox-LDL and also a prolonged lag time of LDL-oxidation. 
Epidemiology and risk factors of cardiovascular disease in renal patients
Enhanced atherosclerosis and consequent increased cardiovascular morbidity 
and mortality are important clinical problems in patients with renal disease on 
dialysis. Mortality from cardiovascular disease in dialysis patients is about 9% 
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per year. This is about 30 times higher than in the general population (12). The 
Framingham Heart Study established the traditional risk factors for developing 
cardiovascular disease. Most of these traditional risk factors (age, diabetes 
mellitus, hypertension, left ventricular hypertrophy, low concentrations of HDL) 
are also present in patients on dialysis treatment and contribute to the high 
incidence of cardiovascular disease in this population. Because of the large 
difference in cardiovascular mortality between the general and the dialysis 
population, it is suggested that in renal failure aggravation of traditional cardio-
vascular risk factors and/or additional cardiovascular risk factors are present. 
The cardiovascular risk factors recognized in dialysis patients are, amongst 
others: anemia, chronic infl ammation, malnutrition, hyperhomocysteinemia, 
hyperparathyroidism, hyperphosphatemia, dyslipidemia and enhanced oxida-
tive stress (13). Two risk factors for cardiovascular disease, i.e. dyslipidemia 
and enhanced oxidative stress, will be discussed further.
Dyslipidemia in renal disease
Dialysis patients suffer from a disturbed lipid metabolism and this contributes 
to the enhanced atherosclerosis and the increased cardiovascular mortality in 
this population (2). Dyslipidemia in this population is characterized abnormal 
composition of the lipoproteins is abnormal and the apolipoprotein profi le is 
disturbed: the concentration of HDL is mostly low whereas concentrations of 
triglycerides and/or very low-density lipoprotein (VLDL) and intermediate-den-
sity lipoprotein (IDL) are increased (2;14). Hypertriglyceridemia is associated 
with the presence of small-dense LDL. This LDL subfraction is believed to be 
highly atherogenic. The precise mechanism of this metabolic disturbance is not 
fully understood, but amongst others, a defective catabolism of triglyceride-rich 
lipoproteins by lipoprotein lipase and hepatic lipase are believed to play a role 
in this process (15). Several authors describe the clinical relevance of dyslipi-
demia in this population. Hocher et al. demonstrated in a hemodialysis popula-
tion, that low concentrations of HDL were associated with all-cause mortality 
(16). Shoji et al. identifi ed IDL, included as part of the LDL, as independent risk 
factor for aortic atherosclerosis (17).
Effects of treatment with statins
The treatment of hypercholesterolemia with statins has been proven to be 
effective and safe and associated with benefi cial effects on mortality in large 
interventional trials (3). Since in these trials patients with severe renal impair-
ment often were excluded, data on effects of statins on clinical endpoints in 
these patients are scarce. In an observational study, Seliger et al. found that in 
a cohort of hemodialysis patients the use of a statin was associated with a 32% 
lower mortality risk (6). Several small, randomized controlled trials with statins 
on biochemical endpoints have been performed in dialysis patients (4;5). The 
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results of these studies are promising: the treatment of dialysis patients with 
statins is safe and effectively improves lipid profi le. Despite the fact that the 
baseline values of total cholesterol and lipoproteins were different, the propor-
tional degree of lipid reduction was similar in all studies and also agrees with 
our present fi ndings. In our study, baseline values of total cholesterol and LDL 
were in the normal range, but treatment with atorvastatin still effectively low-
ered the concentrations of total cholesterol, triglycerides, LDL and improved 
the concentration of apoB. However, the benefi cial effects on cardiovascular 
disease by treatment with statins may not only be determined by the absolute 
reduction of total cholesterol, but also by the reduction of the highly athero-
genic lipoproteins, including ox-LDL particles. Ox-LDL is more atherogenic 
than native LDL: it is immunogenic, has pro-infl ammatory effects and is exces-
sively taken up by macrophages, leading to foam cell formation. We found that 
the levels of ox-LDL were decreased by treatment with atorvastatin and sug-
gest that this reduction possibly can contribute to a lesser degree of athero-
sclerosis. In agreement with this, treatment with statins was found to be associ-
ated with lower levels of C-reactive protein, refl ecting a lower state of chronic 
infl ammation (18). Based on the results of these studies, treatment of renal 
patients with statins might be a promising tool to improve the cardiovascular 
outcome in these patients. Still convincing evidence is lacking for application of 
these drugs on large scale in this population. Large randomized controlled trials 
with statins on cardiovascular morbidity and mortality in dialysis patients are 
underway and these studies will hopefully tell us unequivocally whether to treat 
dialysis patients with statins or not. 
Oxidative stress in dialysis patients
In the pathogenesis of atherosclerosis, oxidative changes in lipoproteins are 
supposed to play a pivotal role. Enhanced oxidative stress is therefore consid-
ered as one of the so-called novel risk factors of cardiovascular disease. Since 
dialysis is associated with oxidative stress, this therapy may seriously enhance 
atherogenesis in this population. It might therefore be worthwhile to search for 
interventional strategies to reduce the amount of oxidative stress.
Treatment with anti-oxidants
Large interventional studies in different populations (both primary and second-
ary prevention) with anti-oxidant therapies have been performed trying to 
improve outcome on cardiovascular morbidity and mortality. However the 
results of these studies are confl icting. The Cambridge Heart Antioxidant Study 
(CHAOS) studied the effects of treatment with vitamin E in populations without 
renal disease (19). A decreased rate of myocardial infarction was observed after 
treatment with vitamin E, although there was no effect on mortality. In the Anti-
oxidant Supplementation in Atherosclerosis Prevention Study (ASAP) it was 
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demonstrated that supplementation with a combination of vitamins E and C 
delayed the progression of atherosclerosis, as determined by ultrasonically 
measurement of the intima media thickness of the common carotid artery in 
hypercholesterolemic patients (20). No effects of both vitamins were observed 
with respect to F2-isoprostanes, a parameter of oxidative stress. In contrast to 
these ‘positive’ studies, the Heart Protection Study (3) and Heart Outcomes 
Prevention Evaluation Study (21) did not demonstrate any benefi cial infl uence 
of intervention with respectively multivitamin and anti-oxidant supplementation 
(vitamin E, vitamin C and ß-caroteen) and vitamin E on clinical endpoints. In the 
GISSI-Prevenzione trial, in which patients with a recent myocardial infarction 
were included, treatment with vitamin E also had no benefi cial effects on car-
diovascular endpoints (22).
The only prospective study with clinical endpoints on vitamin E in a dialysis 
population so far was performed in hemodialysis patients with manifest cardio-
vascular disease (8). It showed that supplementation with vitamin E had benefi -
cial effects on composite cardiovascular disease endpoints and myocardial 
infarction. More interventional studies have been carried out with supplementa-
tion of vitamin E on biochemical endpoints. The results of these studies are not 
unequivocal: some show benefi cial effects on parameters of oxidative stress, 
whereas others do not. The different studies however are hard to compare 
because of the use of different markers of oxidative stress. Beside studies with 
vitamin E supplementation, studies with vitamin E coated membranes have 
been performed in hemodialysis patients. The results of these studies point to 
a reduction in oxidative stress and possibly an improvement of atherosclerosis. 
Prospective studies using these vitamin E coated membranes on clinical end-
points are lacking. 
In the present study we demonstrate that supplementation with 800 IU alpha-
tocopherol daily resulted in a nearly signifi cant increase of resistance of LDL-C 
to oxidation in vitro as refl ected by increased lag time. On the other hand, treat-
ment with alpha-tocopherol slightly increased the concentration of ox-LDL. 
This increase in ox-LDL might be related to a small, insignifi cant increase in 
LDL-C and/or to a pro-oxidative effect of alpha-tocopherol, that can be medi-
ated by defi ciency of co-anti-oxidants (23). Since the ox-LDL/apoB ratio 
remained unchan ged, negative effects of alpha-tocopherol on atherogenesis 
are unlikely. Combination therapy of atorvastatin and alpha-tocopherol led to an 
increase in LDL lag time and a signifi cant reduction in circulating ox-LDL. Since 
the latter effect is also seen in patients treated with atorvastatin only, this results 
most likely from the reduction of plasma LDL. Relative changes in ox-LDL in 
atorvastatin-treated patients were independent of co-addition of alpha-toco-
pherol, suggesting that a pro-oxidative effect of alpha-tocopherol does not 
occur at low concentrations of LDL-C. The slight increase in the ox-LDL/apoB 
ratio that we found in patients treated with atorvastatin and alpha-tocopherol is 
most likely the result of a larger decrease of apoB compared to the decrease of 
ox-LDL. 
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From our study we conclude that treatment with 40 mg atorvastatin once daily 
is effective in lowering plasma total cholesterol, triglycerides, LDL-C, apoB and 
ox-LDL in a population of stable dialysis patients. No side effects were obser-
ved at this rather high dose in this population. These changes in the lipid profi le 
can possibly contribute to improvement of the poor cardiovascular outcome of 
these patients. Ongoing large clinical trials will have to provide the conclusive 
evidence for this. Supplementation of alpha-tocopherol alone did enhance 
resistance to in vitro oxidation of LDL, but on the other hand was associated 
with a slight elevation in plasma ox-LDL levels. Although a causal relation 
between the elevation of circulating ox-LDL and the use of vitamin E is unlikely, 
the clinical benefi t of alpha-tocopherol supplementation alone is questionable. 
However, in combination with a statin, no increase in plasma ox-LDL levels 
occurred and therefore additional alpha-tocopherol supplementation in combi-
nation with a statin may be benefi cial because of the decrease of LDL oxidiz-
ability. 
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Cardiovascular disease is a major problem in patients with end-stage renal 
disease (ESRD). The absolute annual cardiovascular mortality rate in an aver-
age dialysis population is about 10%. Dyslipidemia and enhanced oxidative 
stress are two of the contributors to the enhanced atherosclerosis in this popu-
lation.
Dyslipidemia in ESRD is caused by alterations in the metabolism and the com-
position of the plasma lipoproteins. The typical, traditional lipid profi le in 
patients with ESRD is characterized by normal or low concentrations of LDL-
cholesterol, increased concentrations of triglycerides (TG) due to elevated lev-
els of very-low-density lipoprotein (VLDL) and intermediate-density lipoprotein 
(IDL) and decreased high-density lipoprotein cholesterol (HDL). The LDL com-
position is abnormal and characterized by the presence of small-dense LDL 
particles. Treatment of dyslipidemia by statins in patients with ESRD remains a 
matter of debate. 
Increased oxidative stress is a common fi nding in patients with ESRD. It is 
defi ned as the result of an imbalance between the production of reactive oxy-
gen species, free radicals, and anti-oxidant defences. Oxidative injury can 
change the function and structure of bio molecules like lipids, proteins, carbo-
hydrates and nucleic acids. Oxidized lipids are involved in the initiation and 
acceleration of atherosclerosis. From a theoretical point of view, interventions 
directed at preventing lipid oxidation by anti-oxidants, may have therapeutic 
potential in reducing atherosclerosis, but large randomized controlled trial on 
hard clinical endpoints are scarce.
Chapter 1 is a review of literature data on the relation between cholesterol and 
cardiovascular disease risk in patients with renal failure. Cardiovascular risk is 
increased in patients with chronic renal failure, and is particularly high in 
patients with ESRD. However, in patients with ESRD cardiovascular disease is 
not only characterized by the classical atheromatous atherosclerosis (plaques) 
but also by calcifying blood vessels, myocardial fi brosis and left ventricular 
hypertrophy. Both myocardial fi brosis and left ventricular hypertrophy are likely 
related to rhythm disturbances and sudden cardiac death. 
Epidemiological data show an inverse relation between serum cholesterol con-
centration and cardiovascular events in patients with ESRD. Patients with low 
cholesterol were at highest risk whereas patients with high cholesterol seem to 
be protected against cardiovascular complications. It is now clear that this 
“reverse epidemiology” is caused by confounding due to malnutrition and 
chronic infl ammation. Thus, mortality is high in patients with evidence of chron-
ic infl ammation and malnourishment. These patients are characterized by low 
cholesterol levels, a low body weight and low systolic blood pressure. Indeed, 
in studies that evaluated well nourished patients with ESRD the classical posi-
tive relation between cholesterol and cardiovascular risk became apparent. 
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Still, in most patients with ESRD cholesterol levels are in the normal range, 
therefore other risk factors must be important. These include both traditional 
cardiovascular risk factors such as hypertension, diabetes mellitus, and smok-
ing, as well as so called non-traditional risk factors such as malnutrition, dis-
turbed calcium-phosphate balance and hyperparathyroidism.
In view of these confounding factors and the high incidence of non-classical 
atherosclerotic disease it is no surprise that evidence of the effi cacy of choles-
terol lowering is lacking in patients with ESRD. In our opinion, this absence of 
proof should not lead to therapeutic nihilism. We would argue that cholesterol 
lowering should be considered in patients with known cardiovascular disease 
and patients with ESRD without evidence of malnutrition and infl ammation and 
a reasonable life expectancy. 
In chapter two we compared three different methods of measuring oxidative 
stress in 47 non-diabetic patients with ESRD, just before the start of dialysis, 
and compared these with 41 age- and sex-matched controls. Indirect indica-
tors of free radical activity, such as products of lipid, DNA and protein oxidation 
or serum anti-oxidant activity are often used as a measure for oxidative stress. 
In this study, plasma lipid peroxides, circulating oxidized LDL and lag time of in 
vitro copper-induced LDL-oxidation were assessed. A copper-induced, kinetic 
LDL-oxidation assay, was used to determine the susceptibility of circulating 
LDL to oxidative modifi cation in high-risk populations. More recently, the devel-
opment of monoclonal antibodies to epitopes of ox-LDL made it possible to 
determine directly the amount of ox-LDL particles present in the circulation. An 
increased amount of ox-LDL has been associated with the presence of athero-
sclerosis. We assessed circulating ox-LDL, a promising marker of atherosclero-
sis, in this group of patients with ESRD, not yet treated with dialysis therapy.
We found that levels of lipid peroxides and LDL-oxidation levels were higher in 
patients with ESRD, just prior to the start of dialysis, compared to controls. 
However, this increased oxidative burden was not associated with enhanced in 
vitro oxidizability of LDL. 
Since there are few prospective data of the infl uence of dialysis on lipid profi le 
and oxidative stress, we prospectively investigated the effects of the initiation of 
both hemo- and peritoneal dialysis on lipid profi le and parameters of LDL-oxida-
tion. The results of this study are described in chapter three. Although reducing 
the uremic burden could improve the balance between pro- and anti-oxidant 
effects, repetitive blood membrane contact in hemodialysis induces comple-
ment activation, leukocyte activation and other pro-infl ammatory changes with 
increased production of cytokines and pro-oxidants. We therefore assessed 
lipid profi le, plasma lipid peroxides and lag time of in vitro copper-induced LDL-
oxidation in 46 patients with ESRD just prior to the start of renal replacement 
therapy and after six months. After six months of treatment with hemodialysis 
(n = 33) there was an increase in total cholesterol and triglycerides. In the
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peritoneal dialysis group (n = 13) no differences were observed in the lipid pro-
fi le. During this period, no net effects on oxidative stress as measured by lipid 
peroxides and in vitro copper-induced LDL-oxidation could be demonstrated, 
neither in hemodialysis nor in peritoneal dialysis.
In a single-blind randomized trial of 28 hemodialysis patients, as described in 
chapter four, we investigated the dose-dependent effects of both atorvastatin 
and simvastatin on lipids, C-reactive protein and lag time of in vitro copper-
induced LDL-oxidation. 
Both statin therapies signifi cantly lowered total plasma cholesterol and LDL-
cholesterol concentrations to the same extent, whereas reduction in the con-
centrations of triglyceride-rich particles was less pronounced. Furthermore, 
statin therapy reduced LDL-cholesterol in all LDL subfractions, without altering 
the overall LDL particle density. After both statins plasma high sensitivity 
C-reactive protein (h-CRP) concentrations were not signifi cantly reduced; 
parameters of in vivo LDL-oxidation (plasma ox-LDL concentration and the 
oxidation level of isolated LDL), were signifi cantly decreased. Auto-antibodies 
against ox-LDL, however, did not change during this trial period.
These results indicate that atorvastatin and simvastatin exhibit comparable 
favourable effects on lipid profi les in hemodialysis patients but had no infl uence 
on h-CRP. Moreover, the reduction of in vivo oxidatively modifi ed LDL may indi-
cate that statins exhibit favourable effects on oxidative stress.
In chapter fi ve we present a randomized placebo controlled trial in 44 clini-
cally stable, non-diabetic patients on dialysis therapy (23 on hemo- and 21 on 
peritoneal dialysis) without manifest cardiovascular disease. They were rand-
omized for treatment during a period of 12 weeks with 40 mg atorvastatin + 
placebo alpha-tocopherol once daily, 800 IU alpha-tocopherol + placebo ator-
vastatin once daily, 40 mg atorvastatin + 800 IU alpha-tocopherol once daily, or 
placebo atorvastatin + placebo alpha-tocopherol once daily. Assessment of 
lipid profi le and parameters of oxidative stress were performed at the start and 
after 12 weeks of treatment.
Treatment with atorvastatin reduced total cholesterol, triglycerides, low-density 
lipoprotein cholesterol, apolipoprotein B and levels of ox-LDL with 30-43% but 
had no infl uence on in vitro LDL oxidizability. Additional supplementation with 
alpha-tocopherol had no effect on lipid profi le and ox-LDL levels but decreased 
in vitro LDL oxidizability. No side effects were observed. 
Therefore, it can be concluded that treatment with atorvastatin is effective in 
lowering plasma total cholesterol, triglycerides, low-density lipoprotein, apoli-
poprotein B and ox-LDL in a population of stable dialysis patients. The rele-
vance of these fi ndings is not clear yet. Supplementation of alpha-tocopherol 
to atorvastatin had benefi cial effects on in vitro LDL oxidizability and might 
therefore be of additional value. Further research on the clinical effects of treat-
ment with atorvastatin in combination with alpha-tocopherol is necessary.
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Conclusion and future perspective
Increased oxidative stress in subjects with ESRD is associated with ESRD per 
se, and not with the treatment with hemo- or peritoneal dialysis. 
Attempts in the studies as described in this thesis to diminish oxidative stress 
with statins yielded somewhat confl icting results: the in vivo oxidatively modi-
fi ed LDL was reduced, but no changes in auto-antibodies directed towards 
ox-LDL were observed. No proper explanation for this remarkable discrepancy 
could be found.
In the study with vitamin E, alpha-tocopherol did prolong the lag time of LDL-
oxidation but was also associated with increased levels of ox-LDL when used 
as a single active compound. Only the combined use of statins and vitamin E 
led to both a decrease of concentration of lipids and ox-LDL and a prolonged 
lag time of LDL-oxidation.
All interventions in the presented studies in this thesis were too short and in a 
too small group of patients to allow assessment of possible ameliorating effects 
on primary endpoints.
Still, based on the presented results, a long term study of the combined use of 
vitamin E and a statin should be considered. Alternatively, new approaches to 
control better oxidative stress and low-grade infl ammation in these patients will 
have to be developed. The abysmal cardiovascular outcome in subjects with 
ESRD makes well conducted studies targeting non-classical risk factors man-
datory. As long as we see the vastly increased cardiovascular morbidity and 
mortality rate in such patients, modalities to improve this outcome should be 
assessed. Whether such an improved outcome can be reached with interven-
tion in subjects with already established severe renal insuffciency and/or ESRD, 
is questionable. Modifi able risk factors, such as hypertension and dyslipidemia, 
should be aggressively treated already in early stage of disease, in addition to 
control of protein intake and optimization of calcium and phosphate meta-
bolism. Much effort might have to be directed towards the prevention of severe 
renal insuffi ciency and ESRD, and thus preventing or retarding the further 
acceleration in vascular lesions with increasing renal failure.
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Hart- en vaatziekten zijn een frequent voorkomend probleem bij patiënten met 
terminaal nierfalen. In een gemiddelde dialysepopulatie bedraagt de jaarlijkse 
mortaliteit ten gevolge van hart- en vaatziekten ongeveer 10%.
Dyslipidemie en toegenomen oxidatieve stress zijn hierbij twee van de vele 
cardiovasculaire risicofactoren die bijdragen aan de versnelde atherosclerose.
Dyslipidemie bij patiënten met terminaal nierfalen wordt veroorzaakt door 
veranderingen in het metabolisme en de samenstelling van de lipoproteïnen in 
het plasma. Het lipidenprofi el van deze patiënten kenmerkt zich door normale 
tot lage concentraties LDL-cholesterol, een verhoogde concentratie triglyceri-
den als gevolg van toegenomen hoeveelheid VLDL-cholesterol en IDL-choles-
terol en een verlaagde concentratie HDL-cholesterol. De samenstelling van 
LDL-cholesterol is abnormaal en wordt gekarakteriseerd door de aanwezigheid 
van small-dense LDL deeltjes. Over de behandeling van dyslipidemie in deze 
populatie bestaat geen consensus.
Bij patiënten met terminaal nierfalen is er sprake van een toegenomen mate van 
oxidatieve stress. Dit wordt gedefi niëerd als een verstoring in de balans tussen 
de productie van reactieve zuurstof deeltjes, vrije radicalen en anti-oxidatieve 
bescherming. Oxidatieve beschadiging kan aanleiding geven tot verandering 
van de functie en structuur van biomoleculen zoals vetten, eiwitten, koolhy-
draten en DNA. Geoxideerde lipiden zijn betrokken bij de ontwikkeling van 
atherosclerose. Op theoretische gronden zou behandeling met anti-oxidanten 
zinvol kunnen zijn in de reductie van atherosclerose, echter grote gerandomis-
eerde onderzoeken met klinische eindpunten zijn zeldzaam.
Hoofdstuk één is een weergave van de literatuur over de relatie tussen choles-
terol, oxidatieve stress en hart-en vaatziekten bij patiënten met chronisch nier-
falen. In deze groep is het risico op hart- en vaatziekten verhoogd, waarbij dit 
risico toeneemt met de mate van nierfunctiestoornis. De morfologie van de 
atherosclerose wordt in deze populatie gekenmerkt door zowel klassieke, 
atheromateuze atherosclerose (plaques) als door calcifi cerende bloedvat-
afwijkingen, myocardiale fi brose en linker ventrikel hypertrofi e. Zowel myocar-
diale fi brose en linker ventrikel hypertrofi e zijn gerelateerd aan primaire hartritme-
stoornissen en plotselinge hartdood. 
Epidemiologische data laten een omgekeerde relatie zien tussen de hoogte van 
het serum cholesterol en het risico op hart-en vaatziekten bij patiënten met eind-
stadium nierfalen: patiënten met een laag cholesterol hebben het hoogste car-
diovasculaire risico. Deze ‘reverse epidemiology’ wordt veroorzaakt door con-
founding als gevolg van ondervoeding en chronische ontsteking. De mortaliteit in 
patiënten met tekenen van ondervoeding en chronische ontsteking is hoog. 
Deze patiënten worden gekenmerkt door een laag serum cholesterol, een laag 
lichaamsgewicht en een lage systolische bloeddruk. De klassieke relatie tussen 
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een het serum cholesterol en het cardiovasculaire risico wordt meer zichtbaar 
naarmate de patiënten in een betere voedingstoestand zijn. 
Aangezien in patiënten met terminaal nierfalen het serum cholesterol vaak niet 
verhoogd is, lijkt het aannemelijk dat er andere risicofactoren van belang zijn 
voor het ontwikkelen van hart- en vaatziekten. Zowel de klassieke risicofac-
toren, zoals hypertensie, diabetes mellitus en roken, als niet-klassieke risicofac-
toren zoals ondervoeding, chronische ontstekingsactiviteit en een gestoorde 
calcium-fosfaatbalans met hyperparathyreoïdie spelen hierbij een rol. Vanwege 
deze niet-klassieke risicofactoren en het frequent voorkomen van niet-klassieke, 
calcifi cerende en fi broserende vaat- en myocardschade, is het geen verrassing 
dat er geen bewijs is voor een gunstig effect van behandeling met statines in 
patiënten met eindstadium nierfalen. Het gebrek aan bewijs mag echter in onze 
ogen geen aanleiding zijn tot “therapeutic nihilism”. Verlaging van cholesterol 
zou overwogen moeten worden in patiënten die reeds bekend zijn met hart- en 
vaatziekten en in patiënten zonder tekenen van ondervoeding of chronische 
ontsteking en met een redelijke levensverwachting.
In hoofdstuk twee hebben we de mate van oxidatieve stress in 47 niet-dia-
beten met terminaal nierfalen, voor aanvang van dialyse therapie, vergeleken 
met 41 leeftijds- en geslachtsgematchte controle personen. Plasma lipid per-
oxides, circulerend geoxideerd LDL en in vitro, door koper geïnduceerde, LDL 
oxidatie werden gebruikt als maat voor oxidatieve stress. We hebben aange-
toond dat de concentratie van lipid peroxides en de mate van LDL oxidatie 
hoger waren in patiënten met terminaal nierfalen in vegelijking met controles. 
Deze toegenomen oxidatieve stress kwam echter niet tot uiting in de in vitro 
oxideerbaarheid van LDL. 
Er zijn zeer weinig prospectieve gegevens zijn van de invloed van dialyse op het 
lipidenprofi el en de oxidatieve stress. Daarom hebben wij de effecten van de 
start van zowel hemo- als peritoneaal dialyse op het lipidenprofi el en diverse 
parameters van LDL oxidatie onderzocht. De resultaten van deze studie worden 
beschreven in hoofdstuk drie. 
We hebben het lipidenprofi el en de in vitro, door koper geïnduceerde, oxideer-
baarheid van LDL gemeten in 46 patiënten met terminaal nierfalen vlak voor de 
start met hemodialyse (n=33) of peritoneaal dialyse (n=13). Na zes maanden 
dialyse behandeling met hemodialyse waren de concentraties van cholesterol 
en triglyceriden in het bloed gestegen. In de groep met peritoneaal dialyse wer-
den er geen veranderingen gevonden in het lipiden profi el. We hebben geen 
netto effecten aangetoond van dialyse behandeling op plasma lipid peroxides 
en in vitro LDL oxideerbaarheid. 
In de enkel-blind gerandomiseerde studie in 28 hemodialyse patiënten, zoals 
beschreven in hoofdstuk vier hebben we de dosis afhankelijke effecten van 
zowel atorvastatine als simvastatine op lipoproteïnen, C-reactive protein en de 
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hoeveelheid circulerende ox-LDL deeltjes gemeten. De resultaten van deze 
studie laten zien dat zowel atorvastatine als simvastatine vergelijkbare, gun-
stige effecten hebben op het lipidenprofi el in hemodialyse patiënten maar dat 
deze middelen geen effect hadden op het C-reactive protein. Zowel absoluut 
als procentueel was er een afname te zien in circulerende ox-LDL deeltjes in 
vivo. Dit kan erop duiden dat statines een gunstig effect hebben op oxidatieve 
stress, hoewel de plasma titers van auto-antilichamen tegen geoxideerd LDL 
niet veranderden gedurende de studieperiode.
In hoofdstuk vijf beschrijven we een dubbel blind, gerandomiseerde, placebo 
gecontroleerde studie, uitgevoerd in 44 stabiele, niet-diabeten met terminaal 
nierfalen, zonder klinisch manifest cardiovasculair lijden, die behandeld worden 
met hemodialyse (n=23) en peritoneaal dialyse (n=21). We hebben de effecten 
van atorvastatine, alpha-tocoferol en de combinatie van beide op de lipopro-
teïnen en oxidatieve stress onderzocht. Na behandeling met atorvastatine (40 
mg per dag) was er een aanzienlijke daling van het totale cholesterol, de trig-
lyceriden, het LDL-cholesterol, het apolipoprotein B en van circulerende geoxi-
deerde LDL deeltjes en een minimale daling van het serum vitamine E te zien. 
Behandeling met alpha-tocoferol (800 EH per dag) resulteerde niet alleen in een 
verhoging van de vitamine E concentraties in zowel serum als in LDL deeltjes, 
een vertraging van de LDL oxidatie in vitro, maar ook in verhoogde concentra-
ties van geoxideerd LDL. Behandeling met de combinatie van alpha-tocoferol 
en atorvastatine leidde tot een vertraging van de LDL oxidatie in vitro en een 
daling van concentraties van lipoproteinen en geoxideerde LDL deeltjes. 
Conclusie
De toegenomen mate van oxidatieve stress in patienten met terminaal nierfalen 
is gerelateerd aan het nierfalen op zich en wordt niet beïnvloed door behande-
ling met hemo- of peritoneaal dialyse. 
Pogingen om de oxidatieve stress te reduceren met een statine leidde tot enigs-
zins tegenstrijdige resultaten: de oxideerbaarheid van LDL nam na behandeling 
met een statine wel af, maar er konden geen veranderingen worden aange-
toond in de hoeveelheid auto-antilichamen tegen geoxideerd LDL. Behandeling 
met alpha-tocoferol vertraagde de oxideerbaarheid van LDL maar was 
ge associeerd met een toename van geoxideerde LDL deeltjes. Uitsluitend de 
behandeling met zowel een statine als alpha-tocoferol resulteerde in een 
afname van de concentraties van lipoproteinen en geoxideerd LDL en een ver-
traging van de oxideerbaarheid van LDL deeltjes. 
De interventies in de gepresenteerde studies van dit proefschrift zijn te kort om 
een positief effect op klinische eindpunten te kunnen verwachten. Op basis van 
deze gegevens zou een lange termijn studie op klinische eindpunten, van 
behandeling met de combinatie van een statine en alpha-tocoferol overwogen 
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moeten worden. Anderzijds moet gezocht worden naar betere manieren om 
oxidatieve stress en chronische infl ammatie tegen te gaan. De buitengewoon 
slechte cardiovasculaire prognose van patiënten met terminaal nierfalen recht-
vaardigt daarnaast ook studies naar beïnvloeding van andere niet-klassieke 
cardiovasculaire risicofactoren. Modifi ceerbare risicofactoren zoals hypertensie 
en dyslipidemie moeten, naast beperking van eiwit intake en optimalisatie van 
het calcium- en fosfaat-metabolisme, reeds in een vroeg stadium adequaat 
behandeld worden. Daarbij is het van het grootste belang reeds in een vroeg 
stadium van nierfalen de acheruitgang van de nierfunctie zo veel mogelijk te 
vertragen om ernstig nierinsuffi ciëntie te voorkomen. 
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De Arnhemse en Zwolse patiënten die hebben deelgenomen aan de onder-
zoeken. Het feit dat ik een deel van de patiënten uit de Zwolse onderzoeks-
populatie nu als nefroloog mag behandelen is voor mij erg bijzonder. 
Prof. dr. Henk Bilo. Toen ik in 1997 voor de eerste keer naar Zwolle kwam, was 
ik gewaarschuwd voor jouw grenzeloos enthousiasme voor wetenschappelijk 
onderzoek. Ondanks de waarschuwing ben ik “erin getuind”, met nu dit proef-
schrift als resultaat. Dank voor wat jij hebt mogelijk gemaakt. 
Prof. dr. Anton Stalenhoef. In 1999 kwam ik je vragen of jullie op het laborato-
rium LDL lag time bepalingen voor ons konden doen, ik had niet gedacht dat 
dit uiteindelijk zou leiden tot een proefschrift. Mede dankzij jouw steun is dat er 
toch gekomen. Dank voor je vertrouwen in dit project.
Dr. Berry van Tits. Jij hebt me niet alleen inzicht gegeven in ingewikkelde labo-
ratorium-technieken maar ook altijd snel en waardevol commentaar op de 
manuscripten geleverd. Dank voor je toewijding.
Heidi Lemmers, Helga Toenhake en Magda Hectors. Dank voor jullie fl exibiliteit 
en inzet voor alle bepalingen van “het onderzoek uit Zwolle”. 
Dr. Bert Dikkeschei. Vele dinsdagochtenden zaten we erg vroeg op jouw kamer 
om de voortgang van de BOXER-studies en veel andere zaken te bespreken. 
Jij hebt op het laboratorium in de Weezenlanden de voorwaarden gecreëerd om 
materiaal voor de studies te verzamelen. 
Angela Coppens, Rein Dragt, Marion Fokkert, Anton Huisman en Janine 
Slootra. Ondanks volle vriezers wisten jullie altijd wel weer een plaatsje te 
vinden voor de monsters van dit onderzoek. De rapportage van de uitslagen 
was bij jullie tevens in goede handen.
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Verpleegkundigen van de dialyse-afdeling in Zwolle. Jullie hebben de bloed-
afnames bij de patiënten gecoördineerd en soms ook uitgevoerd. Gelukkig 
ervaar ik nog steeds dagelijks jullie enthousiasme en inzet! 
Dr. Charles Rutten. Probleemloos heb je de controle populatie van de studies 
in hoofdstuk 2 en 3 geleverd. 
Dr. Yu Han Kho. Het bereiden van de vitamine E-drank en het placebo bleek 
een lastige klus. Dankzij jouw inspanningen is dat toch gelukt! 
Prof. dr. Jack Wetzels. Het feit dat we samen hoofdstuk 1 hebben geschreven, 
heeft in belangrijke mate bijgedragen aan het afronden van dit proefschrift. 
Jouw oorspronkelijk denken, pijlsnelle en vlijmscherpe analyses hebben mij 
veel geleerd. Ik hoop je nog lang te mogen consulteren voor lastige klinische 
problemen. 
Dr. Job van der Palen. Jouw hulp bij de statistische bewerking van de data is 
erg waardevol geweest. 
Dr. Geert Kolsters en dr. Joop Offerman. Jullie hebben de patiënten geleverd 
voor de studies uit de hoofdstukken 2,3 en 5. 
Dr. Bas Bredie en dr. Rob van Leusen. Dank voor het mogen meedenken in het 
onderzoek beschreven in hoofdstuk 4.
Judith Hoogendijk-van den Akker. Van mede-auteur in een artikel van jou, tot 
collega in Nijmegen, tot “room-mate” in Zwolle, wie had dat gedacht? Dank 
voor je steun de afgelopen maanden. Het promotie reglement van de Radboud 
Universiteit Nijmegen komt nu aan jouw kant van ons werkblad te hangen. Je 
kunt op me rekenen!
Gertie Smeets. Zonder jou was er geen proefschrift geweest! Bij het verzamelen 
van alle gegevens was jouw geduld eindeloos. Met de nierfalen-poli zijn we ons 
volgende project alweer gestart. Ik ben blij dat je me vandaag als paranimf ter 
zijde zult staan.
Dr. Lielith Ubink-Veltmaat. Talloze keren heb ik bij jou in “the room with a splen-
did view” in het Transitorium mogen werken. Dank voor je waardevolle bijdra-
gen aan deze promotie, maar vooral voor je vriendschap. Ik voel me dubbel 
gesteund met jou als paranimf naast me vandaag.
Gerdi en Wil Besseler, “schoonouders”. Dank voor jullie betrokkenheid en 
bereid heid de helpende hand te bieden bij ons thuis wanneer dat weer eens 
nodig was. 
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Mam en pap. Jullie hebben jezelf regelmatig dingen ontzegd om mij m’n 
ontwikkelingen te kunnen laten maken. Hoewel dat voor jullie vanzelfsprekend 
was, is dit een mooie gelegenheid om jullie daar eens voor te bedanken. Met 
dezelfde vanzelfsprekendheid springen jullie nu regelmatig bij om ons te helpen 
ons gezin draaiende te houden. 
Lieve Sophie en Felix. Jullie kunnen mij niet vaak genoeg laten beseffen wat het 
meest waardevol is. 
Lieve Anne. Onbewust bekwaam heb jij veel bijgedragen aan dit proefschrift. 
Dank voor je liefde en de ruimte die we elkaar geven. 
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Curriculum vitae
Sabine Diepeveen werd geboren op 16 oktober 1968 te Enschede. In 1988 
behaalde zij het VWO examen aan het Jacobuscollege te Enschede. De studie 
geneeskunde werd in 1989 gestart aan de Rijksuniversiteit Groningen, waar in 
1994 de doctoraal fase werd afgesloten. Na haar co-assistentschappen in het 
Medisch Spectrum Twente te Enschede (opleider dr. J.G.M. Jordans), werd in 
1996 het artsexamen behaald. Aansluitend was zij 1 jaar werkzaam als AGNIO 
op de intensive care van datzelfde ziekenhuis. 
In 1997 werd de opleiding tot internist gestart in Ziekenhuis de Weezenlanden te 
Zwolle (opleider dr. G. Kolsters) om in 2000 voor een periode van twee jaar weer 
terug te keren naar het Medisch Spectrum Twente (opleider dr. B.S. Hylkema). 
De opleiding tot internist werd in 2003 in het Universitair Medisch Centrum 
St. Radboud afgerond (opleider prof. dr. J.W.M. van der Meer), waar zij een jaar 
eerder begonnen was met de opleiding tot nefroloog (opleider prof. dr. J.H.M. 
Berden). 
Vanaf maart 2005 is zij als nefroloog werkzaam in de Isalaklinieken te Zwolle. 
Zij woont samen met Anne Besseler en hun twee kinderen Sophie (2001) en 
Felix (2004).
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